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1 Einleitung und Zielsetzung 
 
1 Einleitung und Zielsetzung 
Die dermale Applikation kann zur Behandlung oberflächlicher oder 
systemischer Hautdefekte angewendet werden. Diese Möglichkeit bietet 
gegenüber den klassischen Applikationswegen enorme Vorteile, wie die 
Umgehung des First-Pass Effektes bei oraler Verabreichung oder die negativen 
Auswirkungen invasiver parenteraler Applikationsformen. Um die systemische 
Wirkung zu erzielen muss zuerst die Hauptpenetrationsbarriere, das Stratum 
corneum, überwunden werden. In diesem Fall kann durch Zusatz von 
Penetrationsförderern die Wirkstoffaufnahme verbessert werden. Solche 
verwendete Beschleuniger sind zum Beispiel Tenside bzw. Co-Tenside, aber 
auch die Auswahl der Vehikel spielt eine wichtige Rolle. 
In den letzten Jahren sind Nanopartikel im medizinisch-pharmazeutischen 
Bereich intensiv untersucht worden, jedoch nicht im Hinblick auf die dermale 
Applikation [1]. Daher sollte im ersten Teil der vorliegenden Arbeit geprüft 
werden, ob bestimmte polymere Nanopartikel eventuell einen positiven Einfluss 
auf die Hautpermeation ausüben könnten. Aus diesem Grund sind polymere 
Nanopartikel bestehend aus Chitosan (CS) und Tripolyphosphat (TPP) auf der 
Haut getestet worden. Das erste Ziel war stabile und homogene CS-TPP 
Nanopartikel herzustellen und mit dem Modellarzneistoff Aciclovir zu beladen, 
weiters sollte neben der Erhöhung der chemischen Stabilität eine 
Diffusionsverbesserung des Modellarzneistoffes Aciclovir erreicht werden. Der 
zweite Teil beschäftigt sich mit DPPC Liposomen, mit ihrer Herstellung und 
ihrer physikochemischen Stabilisierung durch Umhüllung mit zwei kationischen 
Polymeren, Chitosan (CS) und Eudragit EPO (EU). Dabei war es das Ziel durch 
die kationischen Gruppen das Zetapotential so stark zu erhöhen, dass keine 
Zerstörung des kolloidalen Systems mehr möglich sein würde. Weiterhin sollten 
diese beiden Polymere durch ihre positive Ladung als Penetrationsförderer für 
die Hautdiffusion der beiden Modellarzneistoffe Aciclovir und Minoxidil dienen. 
Die Diffusionstudien von Aciclovir sind neben der Franz-Zelle zusätzlich mittels 
„Tape Stripping― durchgeführt worden. Die möglichen auftretenden 
Wechselwirkungen der DPPC Liposomen mit Chitosan und Eudragit EPO, 
2 Einleitung und Zielsetzung 
 
sowie auch zusätzlich mit den Arzneistoffen Minoxidil und Aciclovir sollten noch 
mittels der biophysikalischen Methoden ATR-FTIR und microDSC analysiert 
werden. Zusätzlich sollte die FTIR Spektroskopie zur Charakterisierung der 
humanen und porcinen Haut herangezogen werden. Eine 
Konformationsänderung der charakteristischen Lipid Schwingungen nach 
Einwirkung polymer-haltigen und polymer-freien liposomaler Formulierungen 
sollte belegt werden. Darüber hinaus stellte sich die Frage, ob diese Resultaten 
mit jenen der Aciclovir-Hautpenetration ermittelt durch „Tape Stripping― 
korreliert werden können. 
In vorangegangenen Studien konnte gezeigt werden, dass das in der Haut 
vorkommende Phytosphingosin (PS) imstande war die Hautpermeation von 
Fludrocortisonacetat und Flumethasonpivalat zu steigern [2]. Da der 
Wirkungsmechanismus nicht geklärt war, sollten zur Aufklärung weiterführende  
Untersuchungen getätigt werden. Zu diesem Zweck sollten im dritten Teil 
dieser Arbeit erneut Hautdiffusionsstudien, mit dem Ziel durchgeführt werden, 
zu analysieren wie viel PS in der Haut gespeichert bleibt. Dazu wurden DPPC 
Liposomen als Träger eingesetzt. Voraussetzung war eine geeignete sehr 
sensitive Analytik für PS. Es wurde eine Derivatisierung mit o-Phthalaldehyd 
(OPA-Reagens) und anschließender Fluoreszenzdetektion verwendet. Darüber 
hinaus sollten noch mögliche erwartete Wechselwirkungen von PS mit Modell-
Lipiden in DSC-Untersuchungen herausgefunden werden. 
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2 Introduction and Aim of the study 
Dermal applications can be used to treat either superficial or systemic skin 
defects. Such procedures can have tremendous advantages over conventional 
applications, such as avoidance of the first-pass effect and of adverse impacts 
arising from invasive parenteral application forms. To achieve the desired 
effects the main penetration barrier, the stratum corneum, has first to be 
overcome. Penetration can be improved by the addition of penetration 
enhancers. The most commonly used enhancers are surfactants or co-
surfactants, but the range of vehicles can also play an important role.  
In recent years, nanoparticles have been extensively studied in medical as well 
as in pharmaceutical fields, but little is known about their potential to penetrate 
the skin [1]. The first part of this thesis therefore investigated whether polymeric 
nanoparticles can have a positive influence on skin penetration. The effect of 
polymeric nanoparticles consisting of chitosan (CS) and tripolyphosphate (TPP) 
on skin was examined. The first goal was to produce stable and uniform CS-
TPP nanoparticles that could improve penetration and chemical stability of the 
model drug aciclovir.  
The second part of this work deals with DPPC liposomes. Their preparation and 
physicochemical stabilization by coating with two cationic polymers, either 
chitosan (CS) or eudragit EPO (EU), was analysed. Due to their positive charge 
these polymers should enhance the penetration of two model drugs, aciclovir 
and minoxidil. Interactions of DPPC liposomes with the polymers as well as 
with the model drugs were analyzed by FTIR and microDSC. In vitro diffusion 
studies with porcine skin using the Franz-cell model as well as the ―tape 
stripping‖ method were performed to ascertain the penetration profile of 
aciclovir from different liposomal formulations. Moreover, FTIR spectroscopy 
was used to characterise human and different types of porcine skin. Finally, in 
order to find supporting evidence for the tape stripping studies, after skin 
treatment with polymer containing and polymer free liposomal formulations 
conformational changes of skin lipids were analysed by FTIR. 
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Previous studies have shown that phytosphingosine (PS), an active substance 
occurring in the epidermis, improved skin penetration of fludrocortisonacetate 
and flumethasonpivalate [2]. Therefore, in the third part of this thesis skin 
diffusion studies of PS were performed to demonstrate its penetration profile. 
The DPPC liposomes were used as a carrier for PS. In addition, a suitably 
sensitive technique was needed to determine PS content: to increase PS 
analytical sensitivity, PS was derivatised by o-phtalaldehyde (OPA) reagent and 
analysed by HPLC with fluorescence detection. Furthermore, possible 
interactions between the model-lipids and the sphingoid drug were investigated 
by microDSC. 
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3 Background 
3.1 Skin 
3.1.1 Structure and morphology of the skin 
Skin is our largest organ. It is made up of multiple layers of epithelial tissues, 
and guards the underlying muscles, bones, ligaments and internal organs. Due 
to its interfaces with the environment, skin plays a very important role in 
protecting the body from different dangers such as chemicals, bacteria, 
allergens, fungi and radiation. Skin also provides a barrier function that keeps 
moisture in, minimizing transepidermal water loss (TEWL). As figure 1 shows 
skin consists of four layers, stratum corneum (nonviable epidermis, 10-20 µm 
thick), the viable epidermis (50-100 µm thick), dermis and subcutaneous tissue 
as well as of the appendages like hair follicle, sebaceous, sweat glands [3, 4].  
 
 
 
Figure 1 Skin layers: epidermis, dermis and subcutaneous tissue, showing a hair 
follicle, sweat gland, sebaceous gland and other skin appendages 
(http://www.treatment-skincare.com/Glossary/Skin-Structure-Diagram.html access 
date: July 10) 
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Figure 2 represents stratum corneum (nonviable epidermis) and the layers of 
viable epidermis, stratum granulosum, stratum spinosum and stratum basale. 
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Figure 2 Epidermis: stratum corneum, stratum granulosum, stratum spinosum and 
stratum basale (http://www.medscape.com/viewarticle/564078_2, access date: August 
10) 
 
On the basement membrane there is single layer of cuboidal basal 
keratinocytes that divide approximately every 28 days. After division, half of the 
keratinocytes undergo differentiation and become wider and flatter as they 
move towards the outermost skin layer, the stratum corneum. Finally, in the 
stratum corneum the end product of keratinisation process is an array of very 
flat, keratin-filled cells, bounded by cornified envelopes and embedded in a lipid 
matrix (Figure 2) [5]. The outermost layer of the skin, the stratum corneum, is 
only 10–20 µm thick across most parts of the human body, but provides a 
formidable barrier to the passive permeation of drugs [6]. The stratum corneum 
has been also schematically represented as an idealised two-compartment 
model, ―bricks and mortar‖ model, where the corneocytes representing the 
bricks and the lipid lamellae being the mortar (Figure 3) [7]. It has been 
proposed that these intercellular lipids play a fundamental role in the function 
and maintenance of the skin barrier [8]. 
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Figure 3 The multi-layered brick and mortar model of the stratum corneum 
(http://www.pgbeautygroomingscience.com/the-epidermis.html, access date: August 
10) 
 
The physical properties of the lipid mixture of the stratum corneum provide for 
greater permeation resistance than is found with more typical membrane lipids, 
such as phospholipids and cholesterol. According ―to the domain mosaic model 
of the skin barrier‖ suggested by FORSLIND, lipids are organised in ordered 
domains (orthorhombic (OR) and hexagonal (HEX)) connected by lipids in a 
disordered (liquid-crystalline (LIQ)) phase (Figure 4) [9, 10].  
Furthermore, more than one-third of human stratum corneum lipids have chain 
lengths longer than 22 carbons. Compared to the chain lengths of 16-18 
carbons found in the cell membranes of living mammalian cells, this is quite 
remarkable and most certainly has functional implications [10]. 
 
 
 
Figure 4 Molecular organizations of stratum corneum lipids. Scheme of the chain 
conformation  in orthorhombic (OR), hexagonal (HEX), and liquid-crystalline (LIQ) 
phases of long-chain lipids [9] 
 
The intercellular lipids of stratum corneum consist of several different types of 
polar lipids dominated by ceramides (ca. 50 %), cholesterol (ca. 25 %) as well 
as free fatty acids (ca. 10 %) and small amounts of cholesterol sulphate         
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(2-5 %), which plays an important role in the desquamation process of stratum 
corneum [4, 5, 10]. Unlike all other biological membranes, those in the stratum 
corneum do not contain phospholipids [5, 11]. 
Ceramides provide a major component of the barrier function of the stratum 
corneum. The ceramides are structurally heterogeneous.  Humans have 9 
series of ceramides. The base component can be sphingosine, 
phytosphingosine or 6-hydroxysphingosine [12]. The most crucial of all the 
ceramides in the stratum corneum is the ceramid 1 consisting of 
phytosphingosine base with an amid-linked ω-hydroxy fatty acid esterified to 
the ω-hydroxyl group [13]. The other ceramides contain normal or α-hydroxy 
acids amide-linked to one of the bases [12]. Due to its unique structure, 
ceramid 1, an acylceramide, may function as a stabiliser of the intercellular lipid 
lamellae. It is possible that ceramid 1 performing as a ―molecular rivet‖ in the 
intercellular lipid lamellae of the stratum corneum [3, 13]. 
The last ten years have brought interesting observations about the barrier 
function of tight intercellular adhesion between keratinocytes. So called ―tight 
junctions‖ (TJ) play a central role in sealing the intercellular space of cell 
sheets. Within the TJ, aqueous pores or paracellular channels are postulated to 
exist, which allow the controlled diffusion of water and solutes via the 
paracellular pathway [14, 15]. TJ are very complex structures, which consist of 
more than 40 proteins including transmembrane as well as of plaque proteins 
and have been demonstrated only in the stratum granulosum whereas tight 
junctions proteins (claudin 1 and 7) are found in all viable layers as well as in 
skin appendages and dermal blood vessels [14-17]. The TJ and its adhesion 
molecules have not been thought for crucial in the barrier function of the 
epidermis. However, their importance has been demonstrated in skin with 
impaired function (psoriasis or atopic dermatitis) [15, 17]. In addition, it seems 
likely now that modulation of TJ and its structures might lead to changes in skin 
permeability suggesting TJ for good target in skin delivery [17-20].  
Moreover, the epidermis consists of melanocytes, sensory Merkel-cells, 
immunological active Langerhans-cells and lymphocytes beside two major 
keratinic cell types, the first having the capacity to divide and produce new 
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cells, the second serving to anchor the epidermis to the basement membrane 
[3]. 
The next skin layer, the dermis, is tightly connected to the epidermis by a 
basement membrane and provides the nutritive, immune and other support 
systems for the epidermis through the thin papillary layer. The dermis is about 
0.1-0.5 cm thick and consists of collagenous fibres, providing flexibility via 
scaffold of support and elastic connective tissue. The lower reticular layer 
contains the main components of dermis such as blood vessels, lymph vessels, 
hair follicles, and glands that produce sweat (which helps regulate body 
temperature) and sebum, an oily substance protecting skin from drying out [3, 
21]. The subcutaneous tissue or hypodermis is directly underlying the dermis 
and is mainly composed of adipose tissue. This layer is important in the 
regulation of skin and body temperature. The size of this layer varies 
throughout the body and from person to person. Its physiological function 
includes insulation and storage of nutrients and mechanical protection [21].  
Ideally, human skin should be used to evaluate the penetration properties of 
model drugs. However, ethical problems, religious restrictions and limited 
availability make the use of human skin difficult for most researchers. 
Numerous animal models have been used as a substitute for human skin as 
pig, mouse, guinea pig, rat and snake skin. Most of the permeation studies 
conducted in pigs have been performed on their back, on the ear and few on 
the flank or abdomen. Various anatomical and physiological investigations 
show comparable characteristics between human skin and porcine ear skin in 
relation to the stratum corneum, epidermal thickness as well as follicular 
structure and hair density [22]. According to published data, the flux through the 
skin and concentration in the skin were of the same order of magnitude as in 
pig as in human skin, with differences of at most two- or fourfold, respectively 
[23-25]. Recently published results of analyses of the follicular penetration 
report about porcine ear skin being a more suitable in vitro model than excised 
human skin [26]. 
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3.1.2 Mechanisms of skin penetration 
The stratum corneum is known to be a major hindrance to the penetration of 
compounds into the skin. Additionally, molecules applied to the skin contact 
cellular remains, microorganisms, sebum and other materials, which can affect 
penetration. To overcome these structures, the penetrant has two potential 
routes to viable tissue: 
 Transappendageal route  
 Transepidermal pathway (across intact stratum corneum) 
The transappendageal routes circumvent penetration through the stratum 
corneum and therefore are known as the shunt routes. The shunt routes 
include permeation through sweat glands and across the hair follicles. The 
relative importance of the shunt routes versus transport across the stratum 
corneum has been debated by researchers over the years. It is generally 
accepted that as the appendages occupy a fractional area for permeation of 
approximately 0.1%, their contribution to steady state flux of most drugs is 
minimal [25, 27]. This presumption has lead many penetration enhancement 
techniques to concentrate on increasing transport across the stratum corneum 
rather than via appendages [28]. However, resent investigations have shown 
hair follicles may represent an important target for drug delivery as they are 
surrounded by a close network of blood capillaries and dendritic cells [24]. In 
particular, hair follicles appeared to be an important reservoir for particulate 
carrier systems [29-31]. 
The route across the stratum corneum contains intercellular (through the 
intercellular lipid domain) and transcellular pathways (aqueous regions near the 
outer surface of intracellular keratin filaments) [25, 28]. Traditionally it was 
thought that lipophilicity of a compound dictates the partitioning behaviour into 
the stratum corneum; hydrophilic compounds tend to partition into the 
corneocyte´s proteins while more lipophilic compounds into the lipid domain 
[32]. Based on more recent data, the intercellular route is considered to be the 
main passage for permeation of most of the drugs [28, 33] .    
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Below the stratum corneum, the intercellular tight junctions (TJ) are considered 
as one of the major barriers to paracellular transport, transport between or 
around the cells [17]. TJ structure and permeability can be regulated by many 
potential physiological factors, including the concentration of cyclic AMP and 
intercellular Ca2+. By opening the TJ paracellular transport of hydrophilic 
compounds would be allowed [34]. In skin with normal barrier function, the role 
of TJ is still a subject of further investigations [14-17]. 
Little evidence has been found to suggest there are any active processes 
involved in skin permeation. It therefore seems likely that the drug transport 
process is controlled by simple passive diffusion [35]. Fick`s first law (equation 
1) can be used to analyse permeation data and can be simplified to:  
 
where J is the steady-state flux, D is the diffusion coefficient of the drug in the 
stratum corneum over a diffusional path length or membrane thickness (h), K is 
the partition coefficient between the stratum corneum and the vehicle and C0 
the applied drug concentration which is assumed to be constant [28, 35] 
From equation 1 the ideal properties of a drug penetrating stratum corneum 
can be deduced. There are:  
i) Low molecular mass, preferably less than 600 Da,  
ii) Adequate solubility in oil and water,  
iii) High but balanced K (too large may inhibit clearance by viable 
tissues)  
iv) Low melting point (<200°C) [27, 36].  
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3.2 Mechanisms of enhancement 
For successful skin drug delivery, a topical formulation must release drugs into 
the stratum corneum and then from the stratum corneum into the epidermis and 
dermis. Several approaches have been taken to enhance drug transport across 
the skin. They rely either on the use of chemical penetration enhancer, novel 
vehicle systems (e.g. microemulsion, nanoemulsion), lipid-based delivery 
systems and supersaturated formulations or physical enhancement methods as 
iontophoresis, electroporation, ultrasound, microneedle array and others [37]. 
         An ideal penetration enhancer would have following attributes:  
 The enhancement should be immediate and unidirectional, and the 
duration of the effect should be specific, predictable and suitable, 
 After removal of the material from the applied membrane, the tissue 
should immediately fully recover its normal barrier property, 
 The enhancer should show no systemic or toxic effects and not irritate or 
damage the applied membrane surface, 
 The enhancer should be physically compatible with a wide range of 
drugs [34].  
 
In most cases unfortunately, the better a penetration enhancer works, the more 
irritating it is to the skin. For example, chemical enhancers weaken the skin 
barrier by either disrupting or fluidizing the lipid lamellae and/or increase the 
drug solubility and partitioning into the stratum corneum. Chemical permeation 
enhancers collectively refer to a group of compounds spread across different 
structural classes such as organic solvents, fatty acids, surfactants, azone, 
alkyl amins, dimethyl sulfoxide (DMSO) and others [4, 6, 27, 37].  
Another strategy to increase drug uptake is the selection of nanosized carriers. 
These may be categorised as:  
 Nanoparticles (polymeric nanoparticles, solid lipid nanoparticles, 
metallic particles, mineral particles)  
 Lipid based nanoparticles (liposomes, niosomes, transferosomes, 
ethosomes) [1, 27, 38] 
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Nanosized carriers are mostly composed of physiological and biodegradable 
materials, which possess low cytotoxicity and low systemic toxicity. Thus, they 
can be used as an efficient, non-irritating enhancer through the skin [39, 40]. 
Particle size and distribution are very important factors in the completion of 
particles. Batches with wide particle size distributions have shown significant 
variations in drug loading, drug release, bioavailability and efficacy. Other 
important parameters needed to evaluate the suitability of these carrier systems 
are their loading capacity and entrapment efficiency [41].  
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3.3 Nanoparticles 
The benefits of nanoparticles have been shown in several scientific fields, but 
little is known about their potential to penetrate the skin. Nanoparticles may 
enhance percutaneous transport into and across the skin barrier [42]. Particle 
penetration is most likely along two possible routes, the intercellular, following 
the lipids between corneocytes and the appendage, into hair follicles [30, 42]. 
Solid lipid nanoparticles (SLN) are composed of physiological lipids and 
surfactants manufactured by a high pressure homogenisation. Their application 
onto skin induces higher drug penetration. It has been observed that these 
nanoparticles diffuse into the hair follicle [40]. On the other hand, metallic 
nanoparticles, such as gold and iron particles, have been used for dermal 
penetration, and it has been determined that the smallest particles (<15 nm) 
penetrate deeper skin layers, whereas larger particle types (198 nm) only reach 
the viable epidermis. This kind of nanoparticles seem to be able to passively 
penetrate through the SC lipid matrix and the epidermis appendages [31,43]. In 
comparison, mineral nanoparticles as TiO2 and ZnO with sizes between 50-500 
nm, when used as sun-protector agents, remain on the skin surface and do not 
penetrate into the living skin [44, 45]. 
3.3.1 Polymeric nanoparticles 
The carrier technology most commonly used for drug delivery purposes is 
based on polymeric materials, particularly on biomaterial that offer an intrinsic 
biodegradability and biocompatibility. There are already several studies on drug 
penetration from polymeric nanoparticles that have shown a marked difference 
between the conventional and nanoparticulate formulations. Polymeric 
nanoparticles are particles of less than 100 nm diameter that can be prepared 
from natural or synthetic polymers [46]. Biodegradable natural polymers 
exploited to prepare nanoparticles are: chitosan, alginate, gelatine and pullulan. 
Biodegradable synthetic polymers used for nanoparticles production include 
poly-lactic acid (PLA) and poly-lactic-co-glycolic acid (PLGA). 
Nonbiodegradable polymeric nanoparticles can be applied for controlled drug 
delivery and also in diagnostic imaging. Examples of nonbiodegradable 
synthetic polymers used in drug delivery include polymethyl methacrylate (e.g. 
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Eudragit®) while polystyrene agents have been accepted as diagnostic agents 
[41]. Chitosan and Eudragit EPO are the polymers used in the present theses. 
Although polymeric nanoparticles are undoubtedly able to enhance skin 
penetration, the mechanism of enhancement is still unclear. Polystyrene 
nanoparticles have been observed, via confocal laser scanning microscopy, to 
accumulate into the follicles. Interestingly, the smaller nanoparticles (20 nm) 
were more concentrated in the follicular openings than larger nanoparticles 
(190 nm), which could be due to their higher surface area. This has also been 
demonstrated with carriers of micrometer range. Three to ten µm polymeric 
particles selectively penetrated the follicular ducts. Particle larger than 10 µm 
remained on the skin surface, while smaller than 3 µm were randomly 
distributed in the hair follicles and stratum corneum [39]. More importantly, 
polymeric nanoparticles can increase the stability of sensitive drugs by 
protecting the molecules in a polymeric shell [47]. 
Due to its biological properties such as biocompatibility and biodegradability, 
chitosan (CS) has become the most widely used polymer in medical and 
pharmaceutical applications [48]. Chitosan is a polysaccharide composed of 2-
amino-2-deoxy-ß-D-glucan combined with glycosidic linkages and has many 
advantages, particularly for developing micro- or nanoparticles. These include 
its: i) ability to control the release of drugs, ii) solubility in aqueous acidic 
solutions, iii) free amino groups available for cross-linking and iv) cationic 
nature that allows ionic cross-linking with polyanions. Different methods have 
been used to prepare CS particulate system (Table 1). However, selection of 
any of these methods depends upon the nature of the drug as well as the type 
of the delivery device [49]. 
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Table 1 Chitosan based particulate systems [49]        
                                                                                                                                                                                                                            
Type of system Method of preparation 
Microparticles Emulsion cross-linking 
Coacervation/precipitation 
Spray-drying 
Ionic gelation 
Sieving method 
Nanoparticles Emulsion-droplet coalescence 
Coacervation/precipitation 
Reverse micellar method  
Ionic gelation 
Some CS based microparticles have been already evaluated on skin in terms of 
wound-healing properties [49]. In the present theses the ionic gelation method 
was used. This method has attracted much attention because the process is 
very simple [49]. Micro- or nanoparticles are formed by electrostatic interaction 
between the positively charged chitosan (CS) chains and polyanions (Figure 5). 
The most extensively used polyanion is tripolyphosphate (TPP) [48].  
 
 
Figure 5 Interaction of (a) chitosan with (b) tripolyphosphate 
17 Background 
 
Biocompatible chitosan-tripolyphosphate (CS-TPP) nanoparticles have been 
studied with regard to different therapeutic applications. They have shown 
excellent nasal as well as good ocular surface drug delivery [50, 51]. 
Furthermore, it has been found that CS-TPP nanoparticles can be used for skin 
gene therapy [52]. Still, compared with other nanoparticulate formulations, CS-
TPP nanoparticles appear rather unexplored in relation to drug delivery via the 
skin.  
With respect to drug delivery, positive charged amino groups of CS interact with 
negatively charged sites on the cell surface and also possibly with tight 
junctions (TJ), if nanoparticles penetrate the stratum corneum [34, 53]. 
Additionally, CS has good film forming properties and hence it is applied as a 
coating material in drug delivery formulations. CS coated micro- or 
nanoparticles have many advantages over uncoated particles such as 
improvement of drug contents, bioadhesive property and prolonged drug 
release properties [49]. This polymer has been investigated for stabilisation of 
liposomes as well as microemulsion based on lecithin. It has been observed 
that the coating of these lipid based nanostructures increases their stability 
properties [54-56]. 
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3.4 Lipid based particles 
One of the possibilities for increasing the penetration of drugs is the use of 
vesicular systems based on phospholipids. Phospholipids, dispersed in water, 
spontaneously form bilayer membrane vesicles (liposomes) or may act as 
surfactants in forming micro- or nanoemulsions [2, 57].  They have also shown 
to cause less irritation than chemical enhancers such as unsaturated fatty acids 
[58]. The advantage of phospholipids lies in their biocompatibility as they are 
natural components of biological membranes. Hence, phospholipids can be 
generally considered as safe for topical application [59]. 
3.4.1 Liposomes 
Liposomes are spherical structures that contain an aqueous core entirely 
enclosed by one or more concentric spheres of lipid bilayers, composed usually 
of natural (egg yolk or soybean lecithin) and/or synthetic lipids (e.g. dipalmitoyl-
phosphatidylcholine (DPPC), dimirystoyl-phosphatidylcholine (DMPC), 
distearoyl-phosphatidylcholine (DSPC); but other ingredients such as 
cholesterol and ceramides are also possible [27, 60, 61]  Liposomes are 
classified according to the number of bilayers and their diameter into small 
unilamellar vesicles (SUV, 20-100 nm), large unilamellar vesicles (LUV, > 100 
nm) and multilamellar vesicles (MLV, 100 nm – 5 µm) [41]. 
 
 
Figure 6 Structure of an unilamellar liposome 
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Liposomes can be produced by a variety of conventional methods including 
BANGHAM, detergent depletion, ether/ethanol injection, inverted emulsion, and 
reverse phase evaporation. Advanced methods are including freeze drying of 
monophase solution, microfluidic channel, membrane contactor, heating, 
supercritical fluid injection and decompression, supercritical liposome method, 
improved/supercritical reverse phase evaporation and depressurisation of an 
expanded solution into aqueous media. After production they can be modified 
to alter size, lammelarity and homogeneity. The most common methods for 
post-formation processing are sonication, extrusion and high pressure 
homogenization [62]. 
Liposomes have various benefits as drug carriers. They are biodegradable, 
they have low toxicity and they are able to encapsulate hydrophilic drugs within 
an aqueous core and a lipophilic material within the lipid phase [60, 63]. 
However, liposome lipids, like many biomolecules, undergo different 
destabilisation processes. The most common problems are: i) lipids may 
degrade by hydrolysis and oxidation and ii) the physical structure of liposomes 
may be affected by aggregation or fusion [64]. Chemical changes of liposomes 
can be minimised by preparing liposomes from pure lipids and by keeping the 
pH of liposomes close to neutral. The process of liposome fusion can be 
retarded by liposomes storage at low temperature and/or by increasing the 
viscosity of the external media [5]. As an alternative many have attempted to 
use biocompatible polymers (also used in our case) for the surface modification 
of liposomes, obtaining a stabile liposomal system for application in different 
environments [54, 55]. Liposomes stabilisation can also be achieved through 
freeze-drying [5]. 
Due to they have a lipid bilayer, especially liposomes formed from the extracted 
stratum corneum lipids (ceramides, cholesterol and fatty acids), liposomes are 
thought to serve as a model for the skin membrane. They have been employed 
mainly to investigate the mechanisms of action of skin penetration enhancers 
and/or the changes in bilayer organisation by membrane-drug interactions [65, 
66]. Because of the complexity of the skin´s lipids it is common to carry out 
fundamental experiments (FTIR, microDSC) on well characterised phospholipid 
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membranes such as DPPC liposomes, which were used in the present work 
[25].  
 The potential of liposomes for delivering drugs to the skin was first reported by 
Mezei et al. in 1980, who showed five times greater skin delivery from the 
liposomes than an ointment containing the same drug concentration. In therapy 
of psoriasis patients vitamin-A-acid loaded liposomes showed ten times higher 
drug content in the skin in comparison with conventional topical formulations. 
Side effects, skin redness and skin brand, were likewise less presented. 
Minoxidil supplied liposomes also achieved good results in treatment of 
alopecia patients [67].  
 Many studies performed in the last decade showed significantly higher 
absorptions rates as well as greater pharmacological effects for drugs applied 
to the skin while entrapped in liposomes, as compared to ordinary topical 
applications [68, 69]. Still, the mechanism of enhanced drug uptake is not 
completely clear and is being intensively discussed. There are several possible 
mechanisms proposed: i) vesicles penetrate stratum corneum intact, ii) lipid 
bilayer stacks are formed on the surface of stratum corneum, iii) vesicles 
fragments penetrate into the stratum corneum and  finally iv) the vesicles do 
not interact with the stratum corneum. It has been observed by freeze-fracture 
microscopy that intact liposomes are detected mainly in the upper cell layers of 
the stratum corneum, changing its lipid bilayer structure, and do not penetrate 
into its lower regions [70]. This is in accordance with findings of electron 
microscopy studies on humans, where liposomes do not penetrate deeper than 
the horny layer [71]. Other studies have noted phospholipids, as the major 
component of liposomal systems, can easily get integrated with the skin lipids. 
They maintain desired hydration conditions to improve drug penetration through 
the stratum corneum and localisation in the skin layers [72-74]. Moreover, 
recent studies have established the facility of liposomes for drug transport into 
the pilosebaceous units (hair follicles and sebaceous glands) via the follicular 
route [75]. Thus, it is possible that liposomes either find their way into a shunt 
or accumulate in one of the wider space between corneocytes clusters where 
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they can interact with skin lipids or they merge into extended lipidic structures  
on the skin surface and indirectly influence skin permeation [28, 33]. 
 Moreover, many drugs have properties which are far from ideal for dermal 
applications. They may have poor solubility, rapid metabolisation, instability 
under physiological conditions or unfavourable biodistribution leading to 
toxicities. Liposomes can increase therapeutic indications for a variety of drugs 
by alleviating these characteristics [76]. Furthermore, inclusion of drugs in 
supramolecular systems, such as liposomal systems, is an approach of growing 
interest with regard to the problem of light-sensitive drugs. Liposome matrices 
represent one of the most studied photo-protective carriers and successful 
results have been reported in many studies [77].  
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 Abstract 
The aim of the present study was to create a skin delivery system based on 
chitosan-tripolyphosphate (CS-TPP) nanoparticles for aciclovir with enhanced 
chemical stability. In standard diffusion experiments using Franz-type diffusion 
cells, reasonable skin permeability dependent on the particle sizes and CS 
content was shown. Using the method of ionotropic gelation with TPP the 
nanoparticles were formed spontaneously. Two different sizes of aciclovir-
loaded CS-TPP nanoparticles were characterised on their physicochemical 
properties in terms of zeta potential, particle sizes and polydispersity index 
(PDI). The larger the nanoparticle, having a higher CS content, the better the 
aciclovir permeation through porcine skin. Additional differential scanning 
calorimetry (DSC) studies showed a remarkable decrease of the typical 
transition temperature indicating an interaction between skin lipid bilayer and 
CS-TPP nanoparticles. Moreover, the chemical stability of aciclovir was 
significantly increased by the nanoparticle system. After the observation period 
of five weeks, aciclovir incorporated into nanoparticles had undergone photo-
oxidation to a significantly lower extent compared to a pure aqueous solution. 
This degradation product of aciclovir is analysed by using LC-MS, and its 
identity established.  
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: CS-TPP nanoparticles, skin diffusion, aciclovir, DSC, LC-MS 
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1 Introduction 
Chitosan (CS) is a natural cationic polymer obtained by deacetylation of chitin 
using chemical or enzymatic reactions. In the usual sense, CS is chitin with more 
than 40% deacetylation. From the chemical point of view, it is a polycationic 
copolymer consisting of β-(1-4)-linked glucosamine and N-acetylglucosamine 
units. Chitosan is increasingly favoured in various fields of drug delivery for its 
biological properties such as biocompatibility and non-toxicity. CS is metabolised 
by lysozyme which is able to crack the CS into smaller units [1, 2]. Furthermore, 
CS possesses mucoadhesive, wound healing and antimicrobial properties [3, 4].  
The presence of reactive amino groups means that CS can be modified easily to 
create micro- and nanoparticles or porous hydrogels [5]. Chitosan microparticles 
and nanoparticles have been made by chemical cross-linking with different kinds 
of polyanions such as glycyrrhetic acid, polyaspartic acid and other oppositely 
charged molecules, yielding controlled-drug-release formulations with less 
toxicity [6, 7]. One of the most extensively used polyanions is tripolyphosphate 
(TPP). The interaction of CS with TPP leads to the formation of biocompatible 
nanoparticles. The cross-linking density, crystallinity and hydrophilicity of cross-
linked CS allow modulation of drug release and extend its range of potential 
applications in drug delivery [8]. 
Given the successful use of CS-TPP nanoparticles through different barriers in 
recent years, we investigated whether they may also be useful for skin drug 
delivery [9, 10]. The aims of the present study were therefore to create a CS-TPP 
drug delivery system for acyclovir (model drug), to improve its permeability 
through the skin, to enhance the chemical stability of acyclovir by incorporation 
into CS-TPP nanoparticles and to characterise physicochemical properties of the 
new delivery systems. 
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2 Materials and Methods 
 
2.1 Materials 
Chitosan (CS, < 500 kDa) in powdered form was a gift from Syntapharm 
(Mülheim, Germany). The degree of deacetylation was determined by NMR as 
95% [11]. Tripolyphosphate (TPP) and methanol were supplied by Sigma-Aldrich 
Chemie GmbH (Steinheim, Germany). Acyclovir was purchased from Fagron 
GmbH (Barsbüttel, Germany). 
 
2.2 Preparation of CS-TPP nanoparticles 
CS-TPP nanoparticles were prepared using ionotropic gelation between 
positively charged amino groups of chitosan and negatively charged TPP, as 
reported previously by Krauland and Alonso [12]. Briefly, 0.1 g or 0.2 g CS were 
dissolved in 100 ml of distilled water in the presence of 1 N HCl (which is 
essential to achieve protonation of amino groups) under magnetic stirring over 
night at room temperature [13]. TPP aqueous solution (1 ml of about 0.7 mg/ml) 
was added to various volumes of 0.1% CS and of 0.2% CS solution under 
gentle stirring at room temperature in order to obtain different CS : TPP (v/v) 
ratios. The final ratios were obtained by mixing 1 ml TPP with 3.5 ml 0.1% CS 
or 3.5 ml 0.2% CS solution for 10 min. The nanoparticles were formed 
spontaneously and were then concentrated by centrifugation at 24,562×g for 30 
min, at 25°C in glycerol bed (10 µl glycerine). The supernatants were discarded 
and the CS-TPP nanoparticles were resuspended in 100 µl purified water [12]. 
The final pH value of all tested solutions was between 5.3 and 5.5.  
For incorporation of aciclovir into the CS-TPP nanoparticles, aciclovir was 
directly dissolved in the acidic CS solution in a concentration of 0.45 mg/ml, 
following by the procedure described above. 
 
2.3 Effect of pH on formation of nanoparticles 
The pH of the CS solution was adjusted to values in the range from pH 3.5 to 
6.5 by addition of 0.1 mM HCl or NaOH. Different batches of CS-TPP 
nanoparticles were produced by combining these CS solutions with aqueous 
TPP solutions. Each experiment was repeated five times. 
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2.4 Physicochemical characterisation of nanoparticles 
The particle size and polydispersity index (PDI) of the CS-TPP nanoparticles 
were determined by photon correlation spectroscopy; the zeta potential was 
determined by electrophoretic mobility using a Zetasizer Nano ZS (Malvern 
Instruments, Malvern, United Kingdom). For particle size analysis and 
determination of the electrophoretic mobility, samples were diluted with filtered 
distilled water (n=5). 
For calculation of the yield, a fixed volume of the nanoparticles was centrifuged 
at 24,562×g for 40 min at room temperature without a glycerol bed. The 
supernatants were discarded and the microtubes containing the centrifugates 
were frozen at -20°C. The samples were then freeze-dried at -30°C for 3 h 
followed by -55°C overnight. After thawing the samples for 2 h at room 
temperature, the yield was determined by calculating the ratio of the actual 
weight and theoretical weight of the nanoparticles (n=3) [14]. 
 
2.5 Determination of loading capacity and encapsulation efficiency 
To determine loading capacity (LC) and encapsulation efficiency (EE), aciclovir-
loaded nanoparticles were isolated by centrifugation as described above. The 
amount of unbound aciclovir in the discarded supernatant was detected by 
HPLC using a diode array detector (series 200 LC Perkin Elmer, Norwalk, CT, 
USA) at a wavelength of 252 nm. Briefly, supernatants (n=3) were diluted with 
1 N CaCl2 and then centrifuged at 24 562×g for 10 min in order to precipitate 
disturbing polymer residue (we confirmed that the treatment with 1 N CaCl2 did 
not decrease the aciclovir concentration significantly). After filtration (0.45 µm 
pore size), 20 µl of the supernatant were injected onto the system using an 
autosampler (series 200 Perkin Elmer). Separation was achieved using a C-18 
RP column (Nucleosil 100-5, 250 mm x 4 mm, Macherey-Nagel, Düren, 
Germany) at 40°C. The mobile phase consisted of methanol/water 10/90 [15]. 
The flow rate was maintained at 1.0 ml/min. The acyclovir concentration used 
to construct the calibration curve was in the range from 0.05 to 10 µg/ml (n=7). 
The loading capacity and encapsulation efficiency of acyclovir were calculated 
as described below: 
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Loading capacity = 
Total amount of drug-amount of unbound drug   x 100 
                             Nanoparticles weight 
 
      Encapsulation efficiency = 
      Total amount of drug-amount of unbound drug    x 100 
                             Total amount of drug 
 
2.6 Physicochemical stability of nanoparticles at room temperature 
The different batches of CS-TPP nanoparticles with and without aciclovir were 
stored at room temperature for an observation period of six weeks. Particle size 
and zeta potential were monitored weekly using Zetasizer (Nano ZS; Malvern 
Instruments, Malvern, United Kingdom) (n=5). 
 
2.7 Chemical stability of aciclovir in nanoparticles 
The chemical stability of aciclovir incorporated into CS-TPP nanoparticles was 
compared with its stability in aqueous solution. The concentrations of aciclovir 
in CS-TPP nanoparticles and in control sample were the same. The samples 
were stored in Eppendorf tubes under day-light exposure at air-conditioned 
room temperature (approximately 22°C). HPLC analysis (described in 2.4) was 
performed weekly for five weeks (n=3). To characterise the main degradation 
product of aciclovir, an aqueous solution of aciclovir, that had been stored in an 
Eppendorf tube under day-light exposure at room temperature for 2 weeks, was 
analyzed by LC-MS. The analysis was performed on an UltiMate 3000 RSLC-
series system (Dionex, Germering, Germany) coupled to an electrospray 
ionization-3D-ion trap mass spectrometer (ESI-IT-MS) (HCT, Bruker Daltonics, 
Bremen, Germany). Ten µl of the sample were loaded onto a C-18 RP column 
(Nucleosil 100-5, 250 mm x 4 mm, Macherey-Nagel) and eluted into the 
orthogonal ESI source using a 10 min linear gradient of 0-10% methanol (HPLC 
grade) in 5 mM ammonium acetate pH 7.5 at a flow of 1.0 ml/min. The mass 
spectrometer was operated in an automated data-dependent acquisition (DDA) 
mode where each MS scan (m/z 50-400, average of five spectra) was followed 
by a MS/MS scans (m/z 15-300, average of five spectra, isolation window 4 Th) 
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of the most intense precursor ion. Helium was used as collision gas and the 
fragmentation amplitude was 0.40 V in positive ion mode and 0.60 V in 
negative ion mode. Source parameters were as follows: capillary voltage: 4.0 
kV, nebulizer (N2): 60 psi dry gas flow (N2): 12 l/min and dry temperature: 
365°C. For comparison, freshly prepared aqueous solutions of aciclovir and 
guanine hydrochloride were also analyzed. The aciclovir solution containing the 
degradation product was re-analyzed after incubation with 1 M HCl overnight at 
37°C. 
 
2.8 In vitro permeation studies 
In vitro permeation studies with porcine abdominal skin were performed as 
reported previously [16]. About 1 ml of aciclovir-loaded 0.1% or 0.2% CS-TPP 
nanoparticles was applied to the skin surface. Prior to quantification the 
permeated samples were diluted with 1 N CaCl2, centrifuged at 17 586×g for 6 
min and filtered (pore size 0.45 µm). Each batch was quantified in 
quadruplicate following the HPLC method described above. As a control we 
used aciclovir dissolved in water at the same concentration as in the 
nanoparticles (0.45 mg/ml). The pH value of all applied solutions was 
approximately 5.4. 
 
2.9 Differential Scanning Calorimetry  
Differential Scanning Calorimetry (DSC) profiles of thawed and additionally 
dabbed porcine epidermis were obtained using a Perkin-Elmer DSC 7 
differential scanning calorimeter. Sliced skin samples (1 cm2) were impregnated 
for 14 hours with 2 ml water (control), 0.1% CS-TPP or 0.2% CS-TPP 
nanoparticle formulations. The sample weight was in the range of 17-20 mg. 
The samples were placed in aluminium pans and sealed hermetically, than 
heated from 30 to 120ºC at a constant rate of 5ºC/min under a continuous flow 
of dry nitrogen. Transition temperatures reported from all thermograms are 
taken from peak maxima values and from onset temperatures. Gravimetric 
analysis of untreated skin samples prior to DSC experiments showed average 
water content of about 55.7% (w/w) ± 1.44. Treated samples absorbed about 
10% (w/w) ± 7 of used impregnation. 
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2.10 Statistical data analysis 
Results are given as means ± S.D. of at least three experiments. Data were 
exported to the Graph Pad Prism statistics software. Analysis groups consisted 
of independent mean values; the Gaussian distribution of the data was verified 
using the Kolmogorov-Smirnov test. Statistical analysis was performed by one-
way analysis of variance followed by Dunnet‘s or Tukey´s post-hoc tests. 
Values of loading capacity and encapsulation efficiency and results of diffusion 
studies were analysed using paired Student‘s t-test. P < 0.05 was considered 
significant. 
 
3 Results  
 
3.1 Preparation and physicochemical characterisation of pure 
nanoparticles and pH effect 
CS-TPP nanoparticles were established only with particular chitosan : TPP 
ratios (Table 1). Regarding to entanglement of chitosan chains with TPP to 
form particles, a higher content of chitosan resulted in formation of significantly 
larger nanoparticles [17]. This was confirmed by our results (Table 1).  
Table 2 shows that the pH of chitosan solution influenced the particle size and 
PDI values. The size of the nanoparticles did not show any significant 
difference in the pH range from 3.5 to 4.9. From pH 4.9 to 6 they showed 
remarkable swelling behaviour (P < 0.05), and aggregated at pH values higher 
then 6, where chitosan became completely uncharged. The interaction between 
chitosan and TPP was completely destroyed at pH values lower than 3.5, 
resulting in the dissolution of nanoparticles. The zeta potential of successfully 
produced nanoparticles was positive, in the range 22 to 30 mV. 
 
 
 
 
 
 
 
 
 
Table 1 Physicochemical properties of chitosan–tripolyphosphate nanoparticles 
prepared with different ratios (v/v) of 0.1% and 0.2% chitosan and tripolyphosphate 
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CS/TPP 
ratio (v/v) 
Mean particle  
size (nm) 
Polydispersity 
index 
 
Zeta 
Potential 
(mV) 
Yield (%) 
0.1%chitosan 
2/1 
3/1 
4/1 
4,5/1 
5/1 
5,5/1 
6/1 
0.2%chitosan 
2/1 
3/1 
4/1 
4.5/1 
5/1 
5.5/1 
 
Precipitation 
Precipitation 
Precipitation 
350 ± 20 
 368 ± 20* 
 390 ± 10* 
 510 ± 10* 
 
Precipitation 
Precipitation 
450 ± 50 
  634 ± 38** 
  600 ± 50** 
  700 ± 10** 
 
- 
- 
- 
0.14-0.24 
0.21-0.23 
0.22-0.27 
0.22-0.27 
 
    - 
- 
0.4-0.52 
0.12-0.24 
0.6-0.8 
0.9-1.0 
 
 
 
 
 
 
+31± 2                   25.9 ± 1.1 
 
 
 
 
 
 
 
 
+31 ± 2                  40.3 ± 0.8 
Values are means ± SD from at least five experiments. 
Significantly larger particles compared with the *4.5/1 or **4/1 nanoparticles (Dunnet´s test) 
 
 
Table 2 Effect of pH on nanoparticles distribution of 0.1% chitosan-tripolyphosphate 
nanoparticles  
 
 
 
 
 
 
pH Mean particle 
size (nm) 
Polydispersity 
index 
Zeta potential  
(mV) 
    3.5 330 ± 20 0.27-0.29 29 ± 1.1 
4 360 ± 21 0.25-0.26 21 ± 2.1 
4.5 367 ± 14 
 
0.28-0.30 
 
21 ± 0.5 
 4.9 350 ± 21 0.14-0.24 31 ± 2.0 
5.5 500 ± 23* 0.40-0.44 22 ± 1.0 
6 520 ± 26* 0.35-0.36 22 ± 0.8 
6.5 Precipitation - - 
Values are means ± SD from five experiments. *P < 0.05 (Tukey‘s 
test) 
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3.2 Encapsulation of aciclovir within nanoparticles and 
physicochemical properties of nanoparticles 
Incorporation of aciclovir, a poorly soluble substance (1.3 mg/ml in water at 
25°C) into the CS-TPP nanoparticles was optimised by dissolving aciclovir 
directly in the CS solution at a concentration of 0.45 mg/ml. However, an 
increase in particle size with higher CS content did not result in significantly 
higher loading capacity or higher encapsulation efficiency (Table 3). 
 
Table 3 Physicochemical characteristics of acyclovir-loaded 0.1% and 0.2% chitosan-
tripolyphosphate nanoparticles 
 
 0.1% chitosan 0.2% chitosan 
CS/TPP ratio (v/v) 4.5/1 4.5/1 
Mean particle size (nm) 380 ± 50 703 ± 15 
Polydispersity index 0.11-0.21 0.23-0.28 
Zeta potential (mV) +30 ± 3 +27 ± 3 
Loading capacity (%) 6.02 ± 0.4 6.23 ± 0.5 
Encapsulation efficiency (%) 13.56 ± 0.6 14.06 ± 0.4 
Yield (%) 32.6 ± 2.3 44.5 ± 2 
The total amount of acyclovir is 0.45 ± 0.05 mg/ml of CS-TPP solution.  
Values are means ± SD of at least five experiments 
 
3.3 Physicochemical stability of nanoparticles at room temperature  
CS-TPP nanoparticle formulations were unstable at room temperature in terms 
of mean particle size. Cuna et al. explained this property as colloidal system 
tendency to aggregate [14]. 
Our experiments verified this fact for both 0.1% CS (Figure 1) and 0.2% CS 
(Figure 2) nanoparticles. Aggregation ability was much higher in 0.2% CS-TPP 
nanoparticles, showing a significant increase in particle size compared with 
0.1% CS-TPP nanoparticles at each weekly measurement. The particles size of 
the latter was significantly increased after five weeks. The incorporation of 
aciclovir into 0.2% CS-TPP nanoparticles resulted in physical break down after 
two weeks (Figure 2). However, we successfully incorporated acyclovir into 
formulation with 0.1 chitosan; the physical stability of these did not decrease 
within six weeks, evidenced by the stabile zeta potential (Figure 1).  
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Figure 1 Comparison of the physicochemical stability of 0.1% chitosan-
tripolyphosphate nanoparticles with and without aciclovir. Values are means ± SD of at 
least five experiments 
 
0
100
200
300
400
500
600
700
800
0 1 2 3 4
Storage time (week)
M
e
a
n
 p
a
rt
ic
le
 s
iz
e
 (
n
m
)
-40
-30
-20
-10
0
10
20
30
40
Z
e
ta
p
o
te
n
ti
a
l 
(m
V
)
 
Mean particle size                                          Zeta potential 
■ Control nanoparticles                                   ▲ Control nanoparticles 
■ Aciclovir-loaded nanoparticles                      □ Aciclovir-loaded nanoparticles  
Figure 2 Comparison of the physicochemical stability of 0.2% chitosan-
tripolyphosphate nanoparticles with and without aciclovir. Values are means ± SD of at 
least five experiments 
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3.4 Chemical stability of aciclovir in nanoparticles 
Aciclovir is an important antiviral drug used in the treatment of many types of 
herpes infections. However, it has been found that aciclovir degraded under 
exposure to light, oxidants, temperature and in different solvents [15]. 
The HPLC analysis clearly shows a degradation product at a retention time of 
about 1.5 min (Figure 3), which is in agreement with literature data, where the 
photolytic degradation of aciclovir to a non-identified chromophoric compound 
is explained [15]. 
          
(a) 
                          0 day                  after 2 weeks          after 5 weeks 
 
   
(b) 
 
                             0 day         after 2 weeks       after 5 weeks 
Time (min)               Time (min)                 Time (min)
 
 
Figure 3 Chromatograms showing the photolytic degradation of aciclovir in (a) 
water and (b) chitosan–tripolyphosphate nanoparticles after 2 and 5 weeks 
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According to the results of the degradation studies under daylight exposure at 
room temperature, 12% of aciclovir in CS-TPP nanoparticles degraded after 5 
weeks whereas 12% of aciclovir in water had decomposed within two weeks.  
To further characterise the photolytic degradation product of aciclovir, LC-MS 
analysis was performed. Whereas in freshly prepared aqueous solutions only 
aciclovir (3) is detected (Figure 4a), a prominent degradation product (1) is 
formed following two weeks´light exposure at room temperature (Figure 4b). 
This degradation product is different from guanine (2), which is formed by acid-
catalysed hydrolytic cleavage of the N9-linked (2-hydroxyethoxy) methyl-chain 
upon incubation with 1 M HCl overnight at 37°C (Figure 4c). The molecular 
weight of the degradation product (239.1 Da) is 14 Da higher than the mass of 
aciclovir (225.1 Da). From the comparison of the MS2 spectra of aciclovir 
(Figure 5a and 5c) and the degradation product (Figure 5b and 5d), it can be 
concluded that photooxidation of the 2-hydroxyethoxy-group has occured. 
Since the mass spectrometric response of both species in positive and negative 
ion mode is comparable, the photooxidation product is likely to be 9-((2-
hydroxyacetyl) methyl) guanine. 
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Figure 4 HPLC chromatograms (UV trace at 252  nm)  of aqueous solutions of 
(a) freshly prepared  aciclovir, (b) aciclovir stored in an eppendorf tube  under light 
exposure at room temperature for 2 weeks and (c) additionally incubated with 1 M 
HCl  overnight  at 37°C, and (d) guanine hydrochloride. 
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Figure 5 Electrospray ionisation–3D-ion-trap mass spectrometry spectra of (a) the 
[M+H]+ion of aciclovir (226.0→), (b) the [M+H]+ion of the photo-oxidation product 
(240.0→), (c) the [M-H]−ion of aciclovir (224.1→), and (d) the [M-H]−ion of the 
photo-oxidation product (238.1→). The main product ions of aciclovir originate from 
the elimination of the N9-linked (2-hydroxyethoxy) methyl-chain (m/z 152.0 or m/z 
150.0) and the elimination of the 2-hydroxyethoxy group (m/z 162.0). In the case of 
the photo-oxidation product, the fragment ions are interpreted as the elimination of 
N9-linked (2-hydroxyacetyl) methyl-chain (m/z 152.0 or m/z 150.0) and the 
elimination of the 2-hydroxyacetyl group (m/z 164.0). 
 
 
3.5 Skin diffusion  
In the in vitro permeation studies, two different sizes of CS-TPP nanoparticles 
containing aciclovir were applied to porcine skin for 48 hours. The permeation 
of aciclovir was proportional to the nanoparticle size, regulated by the amount 
of chitosan. In other words, larger particle sizes improved the aciclovir diffusion 
through the epidermis. The permeation of aciclovir from larger particles was 
about 1.5-fold higher than from smaller nanoparticles (Figure 6; P < 0.05).  
The diffusion profile of aciclovir from CS-TPP nanoparticles through the 
epidermis was biphasic, reflecting the initial fast partition of aciclovir close to 
the nanoparticle surface followed by a slower diffusion of the drug entrapped 
inside the nanoparticle matrix [17]. According to Figure 6, aciclovir permeation 
after 8 hours was approximately 50% of the drug penetration over 48 hours. 
Therefore, it might be possible to control the penetration of aciclovir by the use 
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of CS-TPP nanoparticles. 
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Figure 6 Comparison of aciclovir permeation through porcine skin from different 
chitosan–tripolyphosphate nanoparticles and aciclovir aqueous solution. Graph 
shows means ± SD of four experiments.  
 
3.6 Differential scanning calorimetry studies 
DSC thermograms of porcine skin with and without treatment are shown in 
Figure 7. It is obvious that the different impregnation types resulted in different 
thermograms. Porcine skin has one endothermic peak at around 78°C which 
corresponds to intracellular lipid layers [18-20].  
Treatment of the skin with water as well as with nanoparticle formulations 
resulted in a shift to significantly lower temperatures (P < 0.05). The maximum 
transition temperature (peak maxima value) was shifted from 78°C for 
untreated skin to 66.5°C after treatment with 0.2% CS-TPP nanoparticles 
(Figure 7). Moreover, a comparison of skin impregnated with 0.2% and 0.1% 
CS-TPP nanoparticles still indicates a significant shift in onset temperature (P < 
0.05) (Table 4).  
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Figure 7 Thermograms of porcine skin 
 
Table 4 Thermal changes after impregnation of porcine skin with water, 0.1% or 0.2% 
CS-TPP nanoparticles  
 
    Impregnation        skin-water 
        (control) 
  
skin-0.1% CS-TPP 
nanoparticles 
skin-0.2% CS-TPP 
nanoparticles 
Peak (°C) 69.82 ± 0.89 67.60 ± 0.53 66.49 ± 0.28 
Onset (°C) 64.82 ± 0.14 63.93 ± 0.31* 62.09 ± 0.25* 
Values are means ± SD ( n>4); *P < 0.05 vs. control (Tukey´s test) 
 
4 Discussion 
CS–TPP nanoparticles were formed by means of electrostatic interaction 
between the positively charged -NH2 groups of chitosan in acidic medium (pH 
4.9) and negatively charged phosphate and hydroxide groups of TPP aqueous 
solution, which compete with each other to interact with -NH3
+ sites of chitosan 
[8]. The nanoparticles were positively charged over the chitosan : TPP ratio 
used, reflecting the excess of chitosan amino groups, which may be favourable 
for drug delivery because of enhanced interaction with negatively charged 
groups on the skin surface. It was also evident that the pH of the chitosan 
solution plays a significant role in the formation of nanoparticles [6]. As a 
consequence of these results, we chose for all further studies nanoparticles 
produced using chitosan solution at a pH 4.9 that gives optimal PDI and zeta 
potential values. The chemical stability of aciclovir was improved by 
incorporation into the nanoparticles, implying successful protection by the 
nanoparticulate system. 
The better permeation of aciclovir from larger nanoparticles could be explained by 
the interaction of positively charged nanoparticles with anionic components of the 
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epithelial cell surface. The surface charge density of larger nanoparticles may 
cause a stronger interaction with the cell surface, resulting in better permeation of 
aciclovir [21].  
 Moreover, the DSC measurements indicate a possible interaction between CS–
TPP nanoparticles and the skin lipids. Interestingly the larger nanoparticles 
interacted more strongly, showing lower onset temperature. 
 
5 Conclusion 
These studies demonstrate that CS-TPP nanoparticles significantly improve the 
chemical stability of aciclovir, and the possible use of CS-TPP nanoparticles for 
delivering aciclovir to the skin. Skin diffusion data showed significantly 
improved permeation of aciclovir from nanoparticles.  
The ratio of CS to TPP is the most important factor for formation of reproducible 
nanoparticles. The size of nanoparticles depends on the chitosan content. 
Increasing the initial chitosan input in the formulation resulted in a larger mean 
particle diameter. The higher the chitosan content the higher the aciclovir skin 
permeation.  
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Abstract 
1,2-Dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) liposomes were 
prepared by high pressure homogeniser and coated with two cationic polymers, 
chitosan (CS) and for the first time Eudragit EPO (EU), respectively. Compared 
to the control liposomes, the polymeric liposomes showed greater 
physicochemical stability in terms of mean particles size and zeta potential at 
room temperature. In the present study, aciclovir and minoxidil have been used 
as hydrophilic and hydrophobic candidates. In the presence of the drugs the 
polymeric liposomes still showed constant particle size and zeta potential. 
Influences of polymers and model drugs on thermotropic phase transition of 
DPPC liposomes were studied by micro differential scanning calorimetry 
(microDSC). The influences on configuration of DPPC liposomes were 
investigated by Fourier transform infrared spectroscopy (FTIR). According to 
DSC results cationic polymers had a stabilising effect, whereas aciclovir and 
minoxidil changed the physical properties of the DPPC bilayers by influencing 
the main phase transition temperature and erasing the pre-transition. The 
investigation of C=O stretching bands of DPPC at 1736 cm-1 in FTIR spectra 
showed that aciclovir has strong hydrogen bonding with C=O groups of DPPC, 
whereas carbonyl groups were free in minoxidil presence. Moreover, the 
coating of liposomes with CS or EU led to higher skin diffusion for both drugs. 
This could be explained as an effect of positive charged liposomes to interact 
stronger with skin negatively charged surface and their possible interactions 
with structures below the stratum corneum.  
 
 
 
 
 
 
 
 
 
Keywords: DPPC, Chitosan, Eudragit EPO, DSC, FTIR, Flux 
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1 Introduction 
Liposomes are spherical structures consisting of one or more phospholipid 
bilayers enclosing an aqueous core and are generally produced from highly 
purified phospholipids extracted from soy oil or egg yolk or synthetic 
phospholipids what is the case in the current study. They have been claimed to 
improve transdermal drug delivery and can be used as a model for the skin 
membrane [1]. Plenty of studies reported that liposomes were able to improve 
skin permeation of various entrapped drugs through the major barrier stratum 
corneum [2]. The possible mechanism of liposomes action on distribution of 
drug through the skin is probably through the fusion of the vesicles either in the 
channel-like structures between corneocytes or in hair follicles or by their 
disintegration of extended lipid structures [3, 4]. 
However, liposomes have some limitations. They generally adhere to each 
other and after certain time fuse to form larger vehicles. As an alternative many 
attempts to use biocompatible polymers for the surface modification of 
liposomes, obtaining a stabile liposomal system for application in different 
environments [2, 5]. Polymers are macromolecule constituents of many useful 
materials that, depending on their molecular structures, can have different 
properties. At present, polymers have applications in many different areas 
including their use as chromatographic material, carriers for molecules and 
cells, for modulation of living processes, changing properties of food products 
and for the development of many pharmaceutical applications. Moreover, 
during the last decade, the use of polymers in drug delivery has been 
extensively studied. 
Chitosan (CS), the natural, bioadhesive, biocompatible and biodegradable 
polymer seems to be an optimal candidate to be combined to liposomes. As a 
cationic biopolymer it showed the ability to improve skin compatibility of skin 
formulations and enhancing effect on the penetration of cosmetic ingredients 
and drugs [6, 7]. Eudragit EPO (EU) was selected for liposome coating as a 
second cationic polymer. This polycation, insoluble at physiological pH 
exhibited mucoadhesive characteristics [8]. Moreover, Alasino et al. showed 
additional membrane destabilising properties and increase in efflux of 
doxorubicin from liposomes [9]. In some studies EU has been regarded as a 
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dissolution modifier. Some other groups used EU´s ability to improve the 
solubility of drugs with low aqueous solubility [10]. 
In the present study three main goals should be achieved: 
i) To increase physicochemical stability of DPPC liposomes in terms of 
mean particles size and zeta potential in the presence and in the 
absence of the drugs by coating with the two cationic polymers, CS and 
EU, respectively. 
ii) To characterise interactions of the polymers and the drugs with DPPC 
by microDSC and FTIR. 
iii) To improve skin permeation of aciclovir and minoxidil by coating with CS 
and EU, respectively.  
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2 Materials and methods 
 
2.1 Materials 
1,2-Dipalmitoyl-sn-glycero-3-phosphatidylcholine was kindly donated by Lipoid 
(Switzerland). The product was synthetic Lipoid PC 16:0/16:0. The content of 
phosphatidylcholine was at least 99 % related to the dry weight. Eudragit EPO 
(EU, <150 kDa, structure is presented in Figure 1) was kindly provided by 
Evonik (Darmstadt, Germany). Chitosan (CS, < 500 kDa) in the powder form 
was a gift from Syntapharm (Mülheim, Germany). The degree of deacetylation 
was determined by NMR with 95% [11]. Aciclovir was purchased from Fagron 
GmbH (Barsbüttel, Germany) and minoxidil from Kwizda (Vienna, Austria). All 
other chemicals used in this study were of analytical reagent grade and were 
used as received without any further purification. 
 
CH3 CH3
CC
H2C
CH3
CH3
R=CH3, C4H9
CH2CH2
 C = O C = O
O
N
OR
 
Figure 1 Structure of Eudragit EPO 
 
2.2 Liposomes preparation  
DPPC liposomes were prepared according to a modified method of Brandl et al 
as described recently [12, 13]. Briefly, the phospholipid powder was dispersed 
in distilled water at 60°C in the concentration of 5% (w/w) and magnetically 
stirred until the powder was completely dissolved and thoroughly mixed using 
an ultra-turax (Omni 500, Glendale, Canada). Afterwards the dispersion was 
homogenised with a high-pressure homogeniser (EmulsiFlex-C3, Avestin, 
Canada) for 16 times at approximately 1100 bar. The liposomes were kept at 
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4°C over night and diluted with purified water 1:1 the day after and 
characterised in terms of mean particles size and PDI. An aqueous dispersion 
of 2% (w/w) of aciclovir and minoxidil, respectively, was added to already 
formed liposomes in the volume ratio 1:1 and afterwards mechanically stirred 
over night at 50°C. 
 
2.3 Chitosan and Eudragit EPO (EU) coated liposomes 
The already prepared liposomes described above were coated with CS and EU 
by adding a polymer solution in volume ratio 1:1 and mechanically stirred for 30 
min. Firstly, different polymer concentrations in 0.01 M acetate buffer ranging 
between 0.125% and 1% (w/w) were used. The final products were determined 
in terms of mean particles size, zeta potential and polydispersity index (PDI). 
For incorporation of aciclovir and minoxidil the liposomes with the lowest 
polymer concentration of 0.125% were used. The drugs were suspended in this 
polymer solution in a concentration of 2% (w/w) and further diluted with 
aqueous liposomes 1:1 (v/v) and stirred over night at 50°C. 
  
2.4 Analysis of size and zeta potential of DPPC liposomes 
The particle size and polydispersity index (PDI) of liposomes were analysed by 
photon correlation spectroscopy, and the zeta potential was determined by 
electrophoretic mobility using a Zetasizer Nano ZS (Malvern Instruments, 
Malvern, United Kingdom). To observe changes of the particles size 
(expressed in Z-average size) and zeta potential, the batches of pure and 
coated liposomes with and without drugs were stored at room temperature over 
a period of twenty weeks. Samples were diluted 1:30 with filtered 0.1 mM 
acetate buffer obtaining conductivity of <0.05 ms/cm and monitored weekly 
(n=5). Each sample was measured three times in 13 runs (sampling time was 5 
and 15 min). 
 
 2.5 Micro-Differential scanning calorimetry (microDSC) studies 
 Differential thermal analysis was performed using a Setaram III micro-
calorimeter as previously reported [14]. Samples of pure and polymer coated 
liposomes, prepared as described above, were scanned. We also performed 
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consecutive runs for each sample [14]. The measurement conditions were: 
1.00°C/min for the scanning rate over the temperature range of 15-65°C, using 
purified water as reference.  
Thermal transitions were calculated using Setsoft 2000 Setaram software. After 
baseline subtraction, raw power data were converted to molar heat capacity 
data. Baselines were fitted to the pre-transition and main transition regions 
using a linear baseline function so that transition temperatures and enthalpies 
of reaction could be calculated for each lipid concentration.  
 
2.6 Fourier transform infrared (FTIR) spectroscopy 
Spectra were recorded on a FTIR spectrophotometer (model: Tensor 27, 
Bruker Optics, Ettlingen, Germany) with a photovoltaic MCT detector at a 
temperature of 25°C. The samples of pure and coated DPPC liposomes with 
and without aciclovir or minoxidil were scanned on Bio-ATR II tool against 
demineralised water as a reference (n=5). 
 
2.7 In vitro aciclovir and minoxidil permeation 
In vitro permeation studies with porcine abdominal skin were carried out as 
previously reported [15]. Briefly, about 0.5 ml of aciclovir and minoxidil loaded 
liposomes with and without coating was respectively applied to the skin 
surface. The diffusion studies were performed for 10 hours with a phosphate 
buffer (pH 7.4) as an acceptor medium, where the samples were taken every 
two hours and measured by HPLC. The HPLC analysis of permeated drug 
(n=4) was carried out on a C-18 RP column (Nucleosil 100-5, 250 mm x 4 mm, 
Macherey-Nagel, Düren, Germany) at 40°C. The mobile phase consisted of 
methanol/water 10/90 for aciclovir and methanol/water/acetic acid 75/25/1 for 
minoxidil [16, 17]. The aciclovir and minoxidil concentrations used to construct 
the calibration curve were in the range from 0.005 to 0.25 mg/ml (n=6). The 
flow rate was maintained at 1.00 ml/min and the injection volume was 20 µl. 
Furthermore, the flux J [μgcm-2h-1] of both drugs in each preparation was 
calculated from the slope of the linear portion of the cumulative amount 
permeated through the porcine skin per unit area versus time plot. 
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2.8 Statistical data analyses 
 Results of current studies are expressed as the means ± SD of four (skin 
diffusion studies) and of five experiments (particle size, zeta potential, 
microDSC, FTIR).  Data were exported to the GraphPad Prism statistics 
software package. Analysis groups consisted of independent mean values and 
the Gaussian distribution of the data was verified using the Kolmogorov-
Smirnov test. Statistics were performed using one-way ANOVA with post-hoc 
Dunnet‘s test. The values of diffusion studies were analysed with 
nonparametric t-test. P values of < 0.05 were considered significant. 
  
 3 Results and Discussion 
 Different preliminary experiments were necessary to optimize the preparation 
process with ultra-turax and following high pressure homogenisation. On the 
one hand we figured out that the temperature of 60°C during the suspension of 
DPPC was very important to obtain reproducible liposomes. On the other hand 
the ultra-turax speed and mixing time had only a small effect on particle size. 
According to a previous investigation sixteen cycles in homogenizer at 1100 
bar were suitable for liposomes production [12, 13]. By monitoring the particle 
size, zeta potential and PDI using light scattering the unloaded liposomes at 
room temperature have shown constant mean particle size, PDI and zeta 
potential for seven weeks (Table 1, P > 0.05). After this time period, the size 
and PDI started to increase significantly (P < 0.05), indicating merging of 
liposomes that could lead to phase separation [18]. Therefore physical stability 
is a general problem with liposomes. As an alternative CS and EU, two cationic 
polymers were employed to improve the stability. As seen in Table 2a and 2b 
the higher the polymer content the larger the particles size, for both polymers 
(P < 0.05). That was the result of the chemical interaction which probably 
involves hydrogen bonding between the polymer and the phospholipid head 
groups on the vehicles surface [7]. The charge of liposomes increased from 
approximately 0.50 to 40 mV with addition of CS or EU. The values of zeta 
potential were almost in the same range independent of the amount of polymer 
(Table 2a and 2b). Finally, both polymers caused stable particle size and 
uniformly PDI values for longer time that could be explained by the positive 
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charge of the particles. Immediately after production, the coated liposomes had 
a zeta potential between 30 and 40 mV and stayed significantly longer 
unaltered than control liposomes (Table 1). The EU coated liposomes have not 
shown any changes within twenty weeks (P < 0.05), while the zeta potential of 
CS coated liposomes decreased after eight weeks and after sixteen weeks 
liposomes started to aggregate resulting in larger particles size and PDI values 
(Table 1).  
Table 1 Physicochemical stability of DPPC, CS DPPC and EU-DPPC liposomes 
expressed in mean particle size as Z-average (MPS), poly dispersity index (PDI) and 
zeta potential (ZP). 
 
 
Week 
 
DPPC 
 
CS DPPC** 
 
EU DPPC** 
  
MPS(nm)±SD 
 
PDI±SD 
 
ZP(mV)±SD 
 
MPS(nm)±SD 
 
PDI±SD 
 
ZP(mV)±SD 
 
MPS(nm)±SD 
 
PDI±SD 
 
ZP(mV)±SD 
 
Start 
 
 
88.15±1.00 
 
0.18±0.01 
 
0.51 ± 0.79 
 
 
97.11 ±1.80 
 
0.27±0.02 
 
40.72±0.79 
 
 
95.66±1.54 
 
0.20±0.01 
 
36.64±0.60 
 
1 
 
87.22±0.71 
 
0.17±0.01 
 
0.50 ± 0.85 
 
 
97.64±0.48 
 
0.23±0.01 
 
40.72±0.80 
 
95.99±0.52 
 
0.20±0,01 
 
31.58±1.56 
 
2 
 
 
89.03±1.29 
 
0.16±0.01 
 
1.02 ± 0.26 
 
 
 
102.80±1.3 
 
0.25±0.01 
 
47.84±1.18 
 
94.53±0.68 
 
0.19±0.01 
 
32.69±0.39 
 
3 
 
85.97±0.42 
 
0.16±0.01 
 
2.00 ± 0.80 
 
 
 
101.72±1.6 
 
0.24 0.01 
 
40.76±1.28 
 
99.38±1.40 
 
0.21±0.01 
 
34.90±0.84 
 
4 
 
86.04±0.44 
 
0.16±0.01 
 
3.23 ± 0.91 
 
 
102.58±0.9 
 
0.24±0.01 
 
40.70±1.99 
 
99.42±1.02 
 
0.20±0.01 
 
38.94±1.50 
 
5 
 
 
84.51±0.48 
 
0.13±0.01 
 
2.12 ± 0.89 
 
 
98.65±0.75 
 
0.23±0.01 
 
36.19±1.11 
 
97.95±1.43 
 
0.20±0.01 
 
38.11±1.31 
 
6 
 
 
88.89±2.07 
 
0.15±0.01 
 
1.15 ± 0.79 
 
 
 
98.55±0.62 
 
0.23±0.01 
 
40.72±1.03 
 
97.97±1.30 
 
0.21±0.01 
 
40.86±4.37 
 
7 
 
90.82±1.28 
 
0.17±0.01 
 
2.18 ± 0.59 
 
 
 
97.73±0.39 
 
0.22±0.01 
 
41.99±3.06 
 
98.54±1.39 
 
0.21±0.01 
 
39.26±0.54 
 
8 
 
100.72±1.9* 
 
0.21±0.02 
 
1.12 ± 0.36 
 
 
95.21±1.22 
 
0.22±0.01 
 
28.29±0.25 
 
98.29±1.50 
 
0.21±0.01 
 
37.94±1.05 
 
9 
 
 
 
 
 
 
173.29±2.0* 
 
0.43±0.01 
 
0.13 ± 0.19 
 
 
95.25±1.3 
 
0.21±0.01 
 
28.29±0.22 
 
94.94±0.81 
 
0.21±0.01 
 
35.66±0.93 
 
10 
 
- 
 
- 
 
- 
 
96.58±0.99 
 
0.22±0.01 
 
23.00±1.16 
 
95.51±0.53 
 
0.21±0.01 
 
36.42±1.16 
 
12 
 
- 
 
- 
 
- 
 
97.65±0.75 
 
0.23±0.01 
 
23.50±3.05 
 
94.78±0.68 
 
0.22±0.01 
 
34.19±0.65 
 
14 
 
- 
 
- 
 
- 
 
98.55±0.62 
 
0.23±0.01 
 
24.10±3.12 
 
95.84±0.34 
 
0.22±0.01 
 
33.63±0.74 
 
16 
 
- 
 
- 
 
- 
 
120.05±0.4* 
 
0.41±0.05 
 
10.00±0.50 
 
93.70±0.94 
 
0.22±0.01 
 
31.44±1,67 
 
18 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
94.05±1.50 
 
0.24±0.02 
 
31.96±0.66 
 
20 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
95.51±0.53 
 
0.21±0.01 
 
36.42±1.16 
Values are means ± SD n=5 
*Significantly larger particles compared with the start (Dunnet´s test). 
**Amount of polymer is 0.125%  
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Table 2a Mean particles size as Z-average (MPS), poly dispersity index (PDI) and zeta 
potential (ZP) of CS-DPPC liposomes 
 
 
    
  Table 2b Mean particles size as Z-average (MPS), poly dispersity index (PDI) and zeta 
potential (ZP) of EU-DPPC liposomes  
 
EU (%) MPS (nm) ± SD PDI ± SD ZP (mV) ± SD 
0 
0.125 
0.25 
0.5 
1.0 
88.15 ± 1.00   
 95.66 ± 1.54* 
  98.42 ± 1.00* 
  100.51 ± 1.30* 
  105.08 ± 1.31* 
0.18 ± 0.01 
0.20 ± 0.01 
0.18 ± 0.01 
0.16 ± 0.01 
0.14 ± 0.01 
0.51 ± 0.79 
36.64 ± 0.60 
38.07 ± 2.13 
35.98 ± 0.96 
32.00 ± 2.92 
Values are means ± SD n=5 
*Significantly larger particles compared with the 0% (Dunnet´s test) 
 
 Microbial growth could not be detected in the polymer containing preparation 
compared to the control DPPC liposomes, which were microbial affected after 
two weeks.  
 As model substances, aciclovir and minoxidil were suspended into the 
described DPPC liposomes and into the coated DPPC liposomes without 
influencing significantly (P > 0.05) their particles size, immediately after 
production (comparing start values of Table 1 with Table 3 and Table 4). 
However, after two weeks of storage aciclovir caused the significant growth of 
particles and PDI values. In contrast to this minoxidil preparations were stabile 
for eight weeks (Table 4). Moreover, an addition of the polymers CS or EU 
induced a higher stabilization effect in all liposome preparations, independent 
of the model drug (Table 3 and 4). Furthermore, in Table 3 and 4, zeta potential 
increased in DPPC liposomes by addition of the drugs, while in coated 
liposomes with minoxidil this was significantly lowered. In the case of aciclovir 
the zeta potential decreased after one week. These results might be suggesting 
CS (%) MPS (nm) ± SD PDI ± SD ZP (mV) ± SD 
0 
0.125 
0.25 
0.5 
1.0 
88.15 ± 1.00 
97.11 ± 0.48* 
108.67 ± 0.64* 
139.87 ± 0.51* 
157.99 ± 2.70* 
0.18 ± 0.01 
0.23 ± 0.01 
0.25 ± 0.01 
0.28 ± 0.01 
0.32 ± 0.04 
0.51 ± 0.79 
40.72 ± 0.79 
42.09 ± 0.75 
40.81 ± 1.38 
41.41 ± 2.26 
Values are means ± SD n=5  
*Significantly larger particles compared with the 0% (Dunnet´s test) 
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drugs association with the lipid bilayer [19]. 
 
Table 3 Mean particles size as Z-average (MPS), poly dispersity index (PDI) and 
zeta potential (ZP) of DPPC formulations with 1% (w/w) aciclovir 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Aciclovir 
Week MPS (nm) ± SD PDI ± SD ZP (mV) ± SD 
    DPPC 
0 
1 
2 
3 
84.48 ± 5.21 
81.10 ± 4.49 
82.54 ± 4.64 
127.53 ± 3.80* 
0.14 ± 0.02 
0.12 ± 0.02 
0.13 ± 0.02 
0.36 ± 0.10 
8.84 ± 2.10 
5.04 ± 0.29 
6.25 ± 2.30 
5.21 ± 1.02  
CS DPPC 
0 
1 
2 
5 
7 
8 
10 
12 
 
 
 
 
10 
 
99.78 ± 0.28 
90.06 ± 4.86 
97.81 ± 4.65 
98.15 ± 4.00 
94.85 ± 1.17 
126.40 ± 3.84* 
135.00 ± 2.20* 
160.00 ± 10.0* 
 
0.19 ± 0.01 
0.19 ± 0.01 
0.16 ± 0.01 
0.17 ± 0.01 
0.19 ± 0.01 
0.25 ± 0.03 
0.27 ± 0.02 
0.37 ± 0.03 
 
38.00 ± 2.79 
23.80 ± 4.49 
20.11 ± 3.45 
23.06 ± 2.62 
16.84 ± 1.40 
17.46 ± 1.49 
17.39 ± 1.09 
19.80 ± 1.20 EU DPPC 
0 
   1 
   2 
   5 
   7 
   8 
  10 
  12 
 
95.92 ± 4.10 
97.00 ± 4.53 
97.35 ± 3.83 
94.55 ± 4.36 
93.57 ± 3.84 
130.60 ± 5.20* 
132.12 ± 3.80* 
144.60 ± 2.00* 
 
0.15 ± 0.01 
0.16 ± 0.02 
0.16 ± 0.02 
0.17 ± 0.01 
0.19 ± 0.02 
0.25 ± 0.03 
0.24 ± 0.03 
0.28 ± 0.03 
 
37.81 ± 2.81 
41.83 ± 3.95 
34.76 ± 9.01 
28.42 ± 2.08 
20.88 ± 3.62 
20.10 ± 2.22 
20.50 ± 2.52 
 
 
 
18.26 ± 1.03 
   Values are means ± SD n=5  
*P < 0.05 vs. week 0 (Dunnet´s test) 
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Table 4 Mean particles size as Z-average (MPS), poly dispersity index (PDI) and 
zeta potential (ZP) of DPPC formulations with 1% (w/w) minoxidil  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Further investigations to clarify and explain the stabilizing effect of polymers 
and possible association of the drugs with the lipid bilayer should be performed. 
Two well established biophysical techniques, microDSC and FTIR were chosen 
for this purpose.  
DPPC liposomes display typical thermotropic phase behaviour with a pre-
transition endotherm near 38.4 ± 0.25°C and the main endotherm near 41.4 ± 
0.05 °C, which corresponds to the gel-to-liquid crystalline (Pß´Lα) phase 
Minoxidil 
Week MPS (nm) ± SD PDI ± SD ZP (mV) ± SD 
    DPPC 
0 
1 
2 
5 
8 
9 
84.41 ± 5.95 
84.02 ± 5.67 
84.28 ± 4.87 
84.51 ± 4.48 
94.67 ± 4.57 
120.50 ± 5.01* 
0.16 ± 0.04 
0.14 ± 0.03 
0.13 ± 0.03 
0.14 ± 0.03 
0.22 ± 0.03 
0.23 ± 0.04  
4.58 ± 0.32 
3.96 ± 0.97 
4.73 ± 0.48 
4.10 ± 0.67 
4.85 ± 1.66 
3.90 ± 1.23 
CS DPPC 
0 
1 
2 
5 
8 
10 
12 
16 
20 
 
94.97 ± 4.23 
96.73 ± 3.87 
96.76 ± 3.96 
96.32 ± 3.85 
96.18 ± 3.06 
94.83 ± 3.51 
97.33 ± 2.20 
96.53 ± 5.02 
95.45 ± 3.02 
 
0.16 ± 0.03 
0.13 ± 0.02 
0.14 ± 0.03 
0.14 ± 0.02 
0.15 ± 0.02 
0.14 ± 0.03 
0.12 ± 0.02 
0.14 ± 0.05 
0.14 ± 0.05 
 
10.80 ± 1.37 
10.51 ± 0.39 
11.41 ± 0.57 
15.62 ± 8.43 
11.06 ± 0.89 
12.87 ± 1.29 
11.64 ± 1.07 
12.60 ± 1.50 
12.35 ± 1.65 EU DPPC 
0 
   1 
   2 
   5 
   8 
   10 
   12 
   16 
   18 
 
94.65 ± 4.33 
93.94 ± 4.89 
95.76 ± 4.89 
94.60 ± 4.87 
94.83 ± 3.91 
95.05 ± 2.59 
95.50 ± 3.56 
101.10 ± 1.26 
 120.40 ± 2.31* 
 
0.13 ± 0.02 
0.14 ± 0.02 
0.13 ± 0.01 
0.14 ± 0.02 
0.16 ± 0.04 
0.14 ± 0.03 
0.18 ± 0.02 
0.20± 0.03  
0.26 ± 0.04 
 
23.84 ± 5.77 
22.80 ± 0.35 
23.96 ± 1.42 
23.06 ± 2.87 
20.29 ± 2.90 
20.90 ± 1.51 
16.10 ± 0.90 
16.30 ± 0.50 
15.30 ± 0.52 Values are means ± SD n=5  
*P < 0.05 vs. week 0 (Dunnet´s test) 
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transition (Table 5). The smaller pre-transition temperature, reflecting the 
lamellar to rippled gel (Lß´ Pß´) transition, has been generally attributed to 
the surface structure of the vehicle and is related to rotations of the 
phospholipid head groups or transformation in the lamellar structure and 
changes in the hydrocarbon chain packing [13].  In the present study, as seen 
in Table 5, an addition of CS and EU could not induce any significant changes 
in the pre and main transition temperature. However, comparing CS and EU 
DPPC liposomes with DPPC liposomes heating curves, the pre transition onset 
temperature shifted significantly to a higher temperature, pointing to the 
interaction with the polar region of the phospholipid bilayer (Table 5). This could 
mean that DPPC molecules get anchored to polymeric chains through 
interaction between their head groups, and the specific functional groups of 
polymer by electrostatic interaction. Moreover the hydroxyl groups of DPPC 
may interact with the hydroxyl groups of polymers through hydrogen bonding, 
stabilizing the lamellar structure of the liposomes what is in coherence with the 
increased physicochemical stability of coated liposomes [20, 21]. Furthermore, 
the pre transition enthalpy is reduced with increased CS or EU content, 
confirming the possibility of their interaction with the liposomes polar domain 
and the interfering with tilting of phospholipid acyl chains (Table 5) [22, 23]. 
Additionally, the enthalpy values of main transition temperature increased 
significantly in the presence of polymers (Table 5), what may be also approving 
an electrostatic interaction between DPPC and polymers. De Oliveira Tiera et 
al. also suggesting that hydrophobic interactions may induce the CS 
incorporation into the lipid bilayer [24].  
Interestingly the addition of the drug resulted in disappearance of the pre 
transition temperature, whereas the main phase transition temperature was 
significantly raised by aciclovir and significantly lowered by minoxidil, (P < 
0.05), (Table 5). This could be described as the substances ability to interact 
with the surface and the phospholipid bilayer [22]. However, the addition of the 
drugs increases the enthalpy main transition significantly confirming the 
interaction with liposomes membrane. In the second and third subsequent 
scans main transition peak and enthalpy remain constant. This means that 
there are no further lipid interactions with the drugs [14]. 
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Table 5 Transition temperature and enthalpy values of DPPC liposomes, DPPC with 
0.125 % (w/w) CS or EU and DPPC with 1% (w/w) aciclovir or minoxidil  
  
 Tmax (°C) Linear Onset (°C) Enthalpy (J/M) 
    DPPC 
 
38.4 ± 0.30 pre transition 
41.4 ± 0.10 main transition 
36.5 ± 0.60 
40.1 ± 0.10 
  1193 ± 121 
30600 ± 430 
 
0.125%CS DPPC 
 
 
1.00%CS DPPC 
 
 
 
 
38.7 ± 0.01 pre transition 
41.4 ± 0.03 main transition 
 
38.8 ± 0.01 pre transition 
41.5 ± 0.01 main transition 
 
 
 
 
 37.9 ± 0.03*  
40.1 ± 0.20  
 
38.1 ± 0.02 
40.2 ± 0.01 
  
 
   
 166 ± 10* 
53000 ± 484* 
 
 102 ± 6* 
54202 ± 469 
 
 
0.125%EU DPPC 
 
 
1.00%EU DPPC 
 
 
  
 
38.7 ± 0.06 pre transition 
41.4 ± 0.01 main transition 
 
38.9 ± 0.05 pre transition 
41.5 ± 0.02 main transition 
 
 
 
37.9 ± 0.03*  
40.1 ± 0.02 
 
38.2 ± 0.01* 
40.4 ± 0.04 
 
 
 145 ± 30* 
51766 ± 967* 
 
    65 ± 10* 
53254 ± 419 
 
 
Aciclovir DPPC  41.9 ± 0.10* main transition 40.3 ± 0.01 54967 ± 200 
Minoxidil DPPC  40.7 ± 0.04* main transition 39.4 ± 0.01 54829 ± 832 
Values are means ± SD n=5 
*P < 0.05 vs. DPPC (Dunnet´s test)  
 
An additional biophysical method is FTIR spectroscopy in aqueous systems 
that can be used to analyze interactions on the molecular level. With this 
technique, it is possible to see subtle changes in the configuration of the lipid 
assemblies by analyzing the frequency and the bandwidth changes of the 
vibrational modes. For this purpose the position of the symmetric and 
antisymmetric CH2 bands at 2800-3000 cm
-1 and C=O stretching mode at     
1736 cm-1 of DPPC were chosen to compare different liposomal formulations 
[25]. 
In a first set of experiments by addition of polymers no shift of the acyl bands at 
2800-3000 cm-1 could be seen in DPPC liposomes implying a stabilization of 
configuration and dynamics of the bilayer. In order to analyze the interaction of 
CS and EU with the glycerol backbone near the head group of the 
phospholipids the C=O stretching band was analyzed. In contrast to previous 
published studies the C=O band at 1736 cm-1 does not shift by addition of 
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solely CS or EU [5] 
In Figure 2 and 3 is clearly seen that this characteristic band of DPPC, arising 
from the ester group vibrations was shifted significantly to lower wave numbers 
in the presence of aciclovir and to higher wave numbers in the presence of 
minoxidil (P < 0.05, Dunnet´s test).  
For all formulations with aciclovir, the lower frequency values suggests that 
hydrogen bonding may occur between the C=O groups of DPPC and either 
with NH2 or OH groups of aciclovir [25-27]. Whereas, the higher frequency 
values for all of minoxidil formulations, indicates no evidence of hydrogen 
bonding, instead there are free carbonyl groups in the system [27]. 
Interestingly, this negative and positive shifting of the C=O band is more 
pronounced in the presence of polymers (Figure 2 and 3). 
 
 
 
Figure 2 FTIR transmission spectra of DPPC (control), DPPC with aciclovir (aci), CS 
DPPC and EU DPPC with aciclovir (aci) (as indicated with arrows) (n=5) 
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Figure 3 FTIR transmission spectra of DPPC (control), DPPC with minoxidil (min), CS 
DPPC and EU DPPC with minoxidil (min) (as indicated with arrows) (n=5) 
 
In the third part of this work, diffusion studies on porcine skin were performed to 
see whether the confirmed interaction between DPPC liposomes and polymers 
could influence the skin permeation of model drugs. As seen in Figure 4 and 5, 
used polymers increased the skin permeation of both model drugs significantly.  
 
 
 
Figure 4 Comparison of aciclovir permeation through porcine skin from different 
liposomal formulations (means ± SD n=4): -▲- EU coated liposomes; -□- CS coated 
liposomes; -○-DPPC liposomes 
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Figure 5 Comparison of minoxidil permeation through porcine skin from different 
liposomal formulations (means ± SD n=4): -■- EU coated liposomes;  
-◊- CS coated liposomes; -○- DPPC liposomes 
  
The coating of liposomes with CS and EU improved the permeation of aciclovir 
1.61-fold and 1.64-fold after 10 hours respectively, in comparison with control. 
In case of minoxidil the skin permeation was 1.54 times higher with CS and 
1.88 with EU (Table 6). One of the reasons for this enhancement could be the 
negative charge on the epithelial cells surface, selective to positively charged 
liposomes [28]. Another reason of this effect might be the tendency of positive 
polymers to disrupt the tight junctions, which was confirmed in the case of CS 
[29]. Wydro et al showed also that CS significantly modifies lipids occurring in 
the skin [21]. 
Table 6 Skin permeation rates of aciclovir and minoxidil from DPPC, CS DPPC and   
EU DPPC and influence of polymers on their permeation through porcine skin  
  
 
 
Model drug 
 
 
Formulation 
 
Cumulative  
amount 
permeated after 
10h (µg/cm²) 
 
Enhancement factor 
of polymers (CS and 
EU) compared to 
DPPC 
 
 
Flux J 
(µg/cm²/h) 
     
Aciclovir DPPC 744.61 ± 54.51 control 77.24 ± 5.5 
125.11 ± 19.5 
126.83 ± 13.9 
 
47.96 ± 5.9 
79.64 ± 13.3 
90.61 ± 5.9 
 CS DPPC 1201.36 ± 203.6* 
 
20203.203.39* 
1.61 
 EU DPPC 1223.21 ± 131.9* 1.64 
    
Minoxidil DPPC 460.56 ± 10.6 control 
 CS DPPC 713.18 ± 50.9* 1.54 
 EU DPPC 866.71 ± 52.6* 1.88 
     Values are means ± SD n=4 *P<0.05 vs. DPPC (t-test) 
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4 Conclusion 
 It can be concluded that the physicochemical stability in terms of mean particle 
size and zeta potential of DPPC liposomes with and without aciclovir or 
minoxidil was significantly increased by addition of two different cationic 
polymers, CS and EU. According to microDSC data this phenomenon can be 
interpreted as hydrogen bonding between the polymer and liposome surfaces. 
Furthermore, FTIR spectra showed that aciclovir has strong hydrogen bonding 
with C=O groups of DPPC, whereas carbonyl groups were free in minoxidil 
presence. This data might be clarifying the longer stability of liposomes with 
minoxidil. The skin permeation efficiency of aciclovir and minoxidil from coated 
liposomes increased, what could be explained as a tendency of positively 
charged liposomes to interact stronger with the skin surface. Another possibility 
to explain this effect is that the CS and EU might be interacting with skin lipids 
and going deeper disrupting the tight junctions in lower epidermis layers.  
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Abstract 
The stratum corneum (SC), top layer of the epidermis, is comprised mostly of 
lipids, which are responsible for the permeability properties of the SC and which 
protect the body from external agents. Changes in these skin micro 
constituents can be understood by instrumental methods such as attenuated 
total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy. The 
present work found that the types of skin analyzed, dermatomed abdominal 
porcine skin, pig ear skin and human heat separated skin, influenced both the 
shape and the intensity of recorded spectra. The typical FTIR spectral bands of 
the conformation of the lipid aliphatic chains in the skin samples were altered 
after treatment with pure DPPC liposomes and chitosan (CS) coated DPPC 
liposomes, but not with aqueous CS-solution. The conformational change could 
be the reason for the various permeability of skin. This was confirmed by tape 
stripping on pig ear skin (imitating in vivo studies): the amount of aciclovir 
penetrating from polymer coated and polymer free liposomes was significantly 
higher under the skin surface in comparison with the aqueous CS-solution. 
Moreover, the addition of the polymer to liposomes induced a higher skin 
penetration than pure liposomes. One explanation might be due to the CS´s 
stronger adhesion to the skin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: FTIR, Tape stripping, aciclovir, DPPC liposomes, cryo TEM 
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1 Introduction 
The stratum corneum (SC) is a distinctive two compartment system, consisting 
of corneocytes embedded in the lipid matrix. The complex structure of the SC 
lipid bilayers is important in maintaining the barrier properties of skin [1, 2]. To 
understand the modification of the lipid organisation within the SC many 
techniques such as X-ray diffraction, IR spectroscopy, DSC, 2H NMR 
spectroscopy and electron microscopy are applied [3-5]. Most of the 
experimental evidences is consistent with the domain mosaic model suggested 
by Forslind et al., in which the skin lipids are organised in ordered domains 
(orthorhombic (OR) and hexagonal (HEX)) connected by lipids in a disordered 
phase (liquid-crystalline (LIQ)) [6-8]. It has been proposed that these domains 
would have crucial impact on SC permeability: the permeability of a disordered 
phase is in general greater than that of the ordered one [4]. According to Wertz 
et al. the greatest flux would be at the phase boundaries [6].  
In the present study Fourier-transform infrared (FTIR) spectroscopy with 
attenuated total reflection (ATR) technique was performed. This is an optimal 
technique in determination of molecular vibration of the components in the SC 
at the functional group level [7]. The FTIR method has already been used to 
characterize the phase transitions of the SC lipids. These transitions were 
detected by shifting of methylen (CH2) bands of the lipid aliphatic chains [1, 2, 
7, 9]. Therefore, in the first step the characteristic CH2 bands of dermatomed 
abdominal porcine skin, pig ear skin and human heat separated skin were 
compared and analyzed. In our last work ATR-FTIR method has been used to 
better understand interactions of the model drugs and two polymers with DPPC 
liposomes [10]. Based on these results, our intention was to further understand 
interactions between skin and different formulations. For this purpose the 
following formulations were applied: DPPC liposomes, chitosan (CS) coated 
DPPC liposomes as well as aqueous CS-solution. The liposomal formulations 
were additionally visualised by cryo-TEM. The question was whether the 
differences between polymer free and polymer containing liposomes could be 
seen. Because the previous studies showed higher aciclovir skin diffusion in 
vitro (Franz-cell model) from polymer coated versus polymer free liposomes 
additional penetration studies using the tape stripping method on pig ear skin 
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were performed [10]. With this method it is possible to investigate the drug 
distribution and penetration layer by layer of topical applied drugs in the SC 
[11-13].  
   
2 Materials and methods 
 
2.1 Materials 
1,2-Dipalmitoyl-sn-glycero-3-phosphatydilcholine (DPPC) was purchased from 
Lipoid (Steinhausen, Switzerland). The product was synthetic Lipoid PC 
16:0/16:0. The content of phosphatidylcholine was at least 99 % related to the 
dry weight. Chitosan (CS < 500 kDa) in the powder form was a gift from 
Syntapharm (Mülheim, Germany). The degree of deacetylation was determined 
by NMR with 95% [14]. Aciclovir was purchased from Fagron GmbH 
(Barsbüttel, Germany) All other chemicals used in this study were of analytical 
reagent grade and were used as received without any further purification. 
 
2.2 Formulations  
Skin samples for FTIR experiments were treated with DPPC liposomes and 
chitosan (CS) coated DPPC liposomes, prepared as previously described [10]. 
Particle size was measured by a Zetasizer Nano ZS (Malvern Instruments, 
Malvern, United Kingdom). The 0.125% (w/w) aqueous CS-solution was 
produced by dissolving the polymer in 0.01M acetate buffer.  
For the tape stripping procedure DPPC and CS coated liposomes were loaded 
with 1% aciclovir as reported [10]. Aciclovir, in aqueous CS-solution, was 
suspended in the same concentration. 
 
2.2.1 Encapsulation of aciclovir in liposomes 
Encapsulation of aciclovir in the liposomes was established by differential 
centrifugation method [15]. Briefly, liposomes and coated liposomes with 
aciclovir were centrifuged at 1200xg for 2 hours at 25°C (Hermle Z323K, 
Wehingen, Germany). The supernatants were removed and dissolved in 96% 
ethanol. Aciclovir content in the supernatants and in the precipitates was 
quantified by HPLC method specified previously (n=3) [10].  
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The encapsulation efficiency of aciclovir was calculated as described below: 
 
 
 
2.3 Skin preparation for FTIR 
2.3.1 Abdominal porcine skin 
The full thickness abdominal skin without hair was dermatomed to a thickness 
of 1.2 mm and then stored frozen at -20°C. Skin samples with dimension of 
about 7.5 cm² (ZnSe crystal dimension) were adopted for the experiment, which 
was performed ten times.  
The following treatments were applied: 
a) Application of 40 µl distilled water 
b) Application of 40 µl pure DPPC-liposomes 
c) Application of 40 µl coated CS-DPPC liposomes 
d) Application of 40 µl aqueous CS-solution 
e) Untreated skin (control) 
After the treatment, the skin samples were placed in PBS buffer and kept at 
37°C or 45°C in a closed petri dish for two hours in each case [4, 9].  
 
2.3.2 Pig ear skin 
The same experimental procedure was repeated on pig ear skin prepared as 
described later (see 2.6.1.).  
 
2.3.3 Human skin      
Human epidermis prepared by heat separation after plastic surgery underwent 
the same experimental procedure as porcine skin [16].  
 
2.4 Attenuated total reflectance-Fourier transform infrared (ATR-FTIR) 
The penetration depth of IR is about 1 µm or less, which includes 
approximately 1–1.5 sheets of cell layers in the SC [9, 17]. Infrared spectra of 
the prepared skin samples were obtained by using FTIR spectrophotometer 
(model: Tensor 27, Bruker Optics, Ettlingen, Germany) with a photovoltaic MCT 
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detector at a temperature of 37°C (physiological temperature) and 45°C 
(transition temperature of SC lipids). To collect the spectra, the skin samples 
were placed stratum corneum down onto the ZnSe ATR crystal (tool: Bio-ATR 
I). To obtain the same intensity of spectra we put the cover glass on the 
sample. For data treatment we used the software OPUS 5.5. 
 
2.5 Cryo-Transmission electron microscopy (Cryo-TEM) 
Liposomes for cryo-TEM were frozen with a Leica EM GP immersion freezer 
(Leica Microsystems, Vienna, Austria) with its environmental chamber a 50 
degC and 90% relative humidity. 4 µl of the specimen diluted to 2.5 mg/ml and 
pre-warmed to 50°C was applied onto glow discharged EM grid coated with 
perforated Quantifoil R3.5/1carbon films (Quantifoil, Jena, Germany). After 30 s 
settling, the suspension was automatically blotted for 0.5-1.0 s with Whatman 
No. 1 filter paper and immediately plunged from the environmental chamber 
into liquid ethane. Subsequently, the specimens were handled only in the 
dehumidified working area and stored in liquid nitrogen prior to microscopy.  
The vitrified specimens were visualised on a Tecnai F30 'Helium' (Polara) cryo-
TEM (FEI Company, Eindhoven, Netherlands) operated at 300 kV and cooled 
with liquid nitrogen. Micrographs were acquired at nominal magnification of 31 
000x and at a defocus of -2.5 µm (high resolution, low contrast) and -8.0 µm 
respectively (high contrast, low resolution) and captured with a Gatan US4000 
CCD camera. 
 
2.6 Tape stripping 
2.6.1 Pig ear skin 
The pig ears were obtained from local butcher and stored in the refrigerator at -
20°C. The night before the tape stripping procedure, the pig ears were stored in 
the fridge at 4°C. On the day of procedure the skin surface was cleaned with 
distilled water, dried and the hair were carefully removed by scissors as closely 
as possible to the surface.  
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2.6.2 Tape stripping  
The pig ears were fixed on a polystyrene support covered with aluminium foil, 
an area of 5X4 cm² was marked with a permanent marker and 5 µl/cm² of the 
tested formulation was applied. After one hour tape stripping was performed as 
described previously using Corneofix® tape strips [11, 18, 19]. Briefly, each 
tape strip was pressed on the skin with the roller over the paper for 5 seconds 
and then removed in a single quick movement. Every tape strip was placed 
onto the special slide frame to determine the mass of the removed SC. The 
pseudo-absorption of the skin corneocytes, which correlates with the protein 
amount on the removed tape strip, was established at 850 nm via infrared (IR) 
densitometer SquameScanTM850A (Heiland electronic, Wetzlar, Germany) as 
described previously [20, 21]. After the removal of 40 tape strips (the most of 
the SC) for all formulations, the model drug (aciclovir) was detectable up to the 
10th strip. Therefore, only 10 strips were taken in all further experiments 
exhibited on 5 additional pig ears. To analyse aciclovir content in different 
layers of the skin, the tape strips (2x2 cm²) were extracted with 4 ml distilled 
water (1ml/cm²) respectively. The tubes were sonicated on ultra sonic bath for 
12 min and afterwards centrifuged for 10 min. Aciclovir content was detected by 
HPLC using the method described previously [10].  
 
2.6.3 Transepidermal water loss (TEWL) measurements 
The main aim of TEWL measurements was to characterise the barrier property 
of the pig ears. TEWL was recorded with closed chamber device (AquaFluxTM, 
Biox, London, UK) before and after the tape stripping procedure. 
Measurements were performed in triplicate and AquaFlux® V6.2 software was 
used for data analysis. 
 
2.7 Statistics 
Results of all studies are presented as the means of at least three experiments 
± SD. Data were exported to the GraphPad Prism statistics software package 
(GraphPad Prism Software, USA). Analysis groups consisted of independent 
mean values and the Gaussian distribution of the data was verified using the 
Kolmogorov-Smirnov test. A statistical analysis was performed using one-way 
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ANOVA with post-hoc Dunnet‘s or Tukey‘s test. P-values of < 0.05 were 
considered significant. 
 
3 Results and discussion  
 
ATR-FTIR spectroscopy is a non-invasive technique for characterisation of the 
SC at a molecular level. Different attempts have been made to present IR 
spectra of skin [2, 3, 9]. In the present study IR spectra of dermatomed 
abdominal porcine skin, pig ear skin and human heat separated skin are 
compared (Fig.1). The following skin bands obtained from skin intercellular 
lipids and keratin (corneocytes) were of interest: CH2 asymmetric (~2920 cm
-1) 
and symmetric stretching vibration (~2850 cm-1), CH2 scissoring mode between 
1470 and 1460 cm-1, amid I (C=O) vibration at about 1640 cm-1 and amid II (C-
N) vibration at about 1540 cm-1 as well as C=O stretching band from the fatty 
acids at about 1740 cm-1 [7, 9] . In Fig. 1 it can be clearly seen that the human 
heat separated skin shows similar spectra to the dermatomed abdominal 
porcine skin as well as to the pig ear skin. 
 
 
 
Figure 1 Comparison of FTIR transmission spectra at 37°C of untreated pig abdominal 
dermatomed, pig ear and human skin (from top to bottom)  
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These different skins have been employed for studying the influence of different 
formulation treatments on the characteristic vibration of the IR-spectra. For this 
purpose preliminary experiments were necessary. The amount of formulation 
applied, number of treatments and time of impregnation were optimised. The 
amount of 40 µl formulation to be used was established according to the length 
of time taken to be absorbed by the skin. This was in agreement with already 
published data [4, 9]. Procedures using repeated applications and longer 
impregnation periods have not shown any significant differences in the 
obtained spectra (data not shown). According to the investigations undertaken, 
an application of 40 µl formulation impregnated with skin for 2 h was found to 
be optimal for spectra interpretation. In Tables 1 and 2 the band wavenumbers 
of different skin spectra (37°C and 45°C) impregnated with pure DPPC, CS 
coated liposomes as well as with the aqueous CS-solution and distilled water 
respectively, are presented. The control modes (untreated skin) in all spectral 
regions, except the C=O region of pig ear skin and human skin, remained 
unaltered by an increase of temperature from 37° to 45°C. This contrasts with 
data published by other authors that did show change across this temperature 
range [4, 9, 22].  
Of particular interest for studying the interaction of the formulations with SC 
lipids are CH2 stretching bands. Analyses of these bands provide information 
about conformational order (trans-gauche isomerisation) of the lipid alkyl chains 
[4, 23, 24]. After the treatment dermatomed porcine skin and human skin with 
liposomal formulations, symmetric and asymmetric methylene stretching bands 
were shifted to significantly lower values compared with the control samples, 
indicating a lipid order-disorder transition from the gel to the liquid-crystalline 
state (Table 1 and 2). This transition involves also an increase in the fluidity of 
the SC lipids that could increase the skin penetration [4]. However, the same 
treatments of pig ear skin showed the shift of symmetric stretching band to the 
lower values only at 45°C.  
The region corresponding to CH2 scissoring vibration provides information 
about the lateral packing of lipid alkyl chains in the SC. In all skin samples at 
both temperatures (37° and 45°C) CH2 scissoring band displayed a doublet, 
characteristic of the orthorhombic (OR) lattice, which is very important for the 
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barrier function of the lipids (Table 1 and 2) [9, 25]. This doublet is caused by 
short-range interaction between the CH2 in the lipid tails [22]. The spilt of the 
band is indicative of the degree of inter-chain interaction and the size of the 
domain with OR organisation. In the spectra of the pig ear skin the scissoring 
width was ~10 cm-1 indicating a high content of OR phase. The corresponding 
value observed in dermatomed porcine skin and human skin was ~ 6 cm-1 
displaying lower content of OR phase and higher conformational disorder of the 
lipid chains than in pig ear skin [2]. The treatment with liposomal formulations 
showed slight increase of width of the doublet at both temperatures (Table 1 
and 2). In conclusion, the FTIR data suggest that the SC barrier function is 
partially overcome by liposomal application. 
 
Table 1 ATR-FTIR values of characteristic bands of different skin modes at 37°C  
 
 
 
 
 
Impreg
nation 
 
Dermatomed porcine skin modes (cm
-1
) 
 
 
 
Pig ear skin modes (cm
-1
) 
 
 
 
Human skin modes (cm
-1
) 
    
CH2 
sym.str
etching 
CH2 
asym. 
stretchi
ng 
 
C=O 
CH2 
scissori
ng 
CH2 
sym.str
etching 
CH2 
asym.s
tretchin
g 
 
C=O 
CH2 
scissori
ng 
CH2 
sym.str
etching 
CH2 
asym.s
tretchin
g 
 
C=O 
CH2 
scissori
ng 
 
Control 
 
 
2922.0 
 
2852.5 
 
1743.5 
 
1458.1 
1463.9 
 
2918.1 
 
2850.6 
 
1741.6 
 
1456.1 
1465.8 
 
2922.0 
 
2852.5 
 
 
1743.5 
 
1458.1 
1463.9 
 
Water  
 
2922.0 
 
2852.5 
 
1743.5 
 
1458.1 
1463.9 
 
2918.1 
 
2850.6 
 
1741.4 
 
1456.1 
1465.8             
 
2922.0 
 
2852.5 
 
1743.5
 
 
1458.1 
1463.9 
 
DPPC 
 
 
2918.1
a 
 
2850.6
a 
 
1742.2
a 
 
1456.1 
1467.1
 
 
2918.1 
 
2850.6 
 
1738.4
a 
 
1456.1 
1467.7
 
 
2920.0
a 
 
2850.6
a 
 
1743.5 
 
1458.1 
1465.8
 
 
CS-
DPPC 
 
2918.7
a 
 
2850.6
a 
 
1741.6
a 
 
1456.1 
1465.8
 
 
2918.1 
 
2850.6 
 
1738.4
a 
 
1456.1 
1467.7
 
 
2920.0
a 
 
2850.6
a 
 
1743.5 
 
1458.1 
1465.8
 
 
CS-
solutio
n 
 
 
2922.0 
 
2852.5 
 
1743.5 
 
1458.1 
1463.9 
 
2918.1 
 
2850.6 
 
1741.2 
 
1456.1 
1465.8 
 
2921.3 
 
2852.5 
 
1743.5
 
 
1458.1 
1463.9 
Values are means of n=10 
a
Significantly decreased values compared with the control (Dunnet´s test) 
 
 
 
 
72 Specific topics 
 
Table 2 ATR-FTIR values of characteristic bands of different skin modes at 45°C  
 
 
 
 
 
Impreg
nation 
 
Dermatomed porcine skin modes (cm
-1
) 
 
 
 
Pig ear skin modes (cm
-1
) 
 
 
 
Human skin modes (cm
-1
) 
    
CH2 
sym.str
etching 
CH2 
asym. 
stretchi
ng 
 
C=O 
CH2 
scissori
ng 
CH2 
sym.str
etching 
CH2 
asym.s
tretchin
g 
 
C=O 
CH2 
scissori
ng 
CH2 
sym.str
etching 
CH2 
asym.s
tretchin
g 
 
C=O 
CH2 
scissori
ng 
 
Control 
 
 
2922.0 
 
2852.5 
 
1743.5 
 
1458.1 
1463.9 
 
2918.1 
 
2850.6 
 
1743.5 
 
1456.1 
1465.8 
 
2922.0 
 
2852.5 
 
 
1745.1 
 
1458.1 
1463.9 
 
Water  
 
2922.0 
 
2852.5 
 
1743.5 
 
1458.1 
1463.9 
 
2918.1 
 
2850.6 
 
1743.5 
 
1456.1  
1465.8             
 
2922.0 
 
2852.5 
 
1745.1 
 
1458.1 
1463.9 
 
DPPC 
 
 
2919.4
a 
 
2850.6
a 
 
1742.2
a 
 
1458.1 
1465.8
 
 
2916.1
a 
 
2850.6 
 
1738.4
a 
 
1456.1 
1467.7
 
 
2918.7
a 
 
2850.6
a 
 
1742.9
a 
 
1456.1 
1465.8
 
 
CS-
DPPC 
 
2918.7
a 
 
2850.6
a 
 
1741.6
a 
 
1458.1 
1465.8
 
 
2916.8
a 
 
2849.3 
 
1737.1
a 
 
1456.1 
1467.7
 
 
2918.1
a 
 
2850.6
a 
 
1742.9
a 
 
1456.1 
1465.8
 
 
CS-
solutio
n 
 
 
2922.0 
 
2852.5 
 
1743.5 
 
1456.1 
1463.9 
 
2918.1 
 
2850.6 
 
1741.2
a 
 
1456.1 
1465.8 
 
2921.3
a 
 
2852.5 
 
1745.4
a 
 
1458.1 
1463.9 
 Values are means of n=10 
a
Significantly decreased values compared with the control (Dunnet´s test) 
 
In order to obtain more insight into structure of the liposomes cryo-TEM was 
applied. As seen in Fig. 2 there were mainly multivesiculare liposomes [26]. 
The difference in liposomes induced by polymers could not be visualised by this 
technique. However, comparing Fig. 2a and Fig. 2b, CS containing liposomes 
seem to be more distant from each other. This could be explained by the 
positive charge of CS, which decreased the tendency of liposome-aggregation, 
resulting in their longer stability.  
Furthermore, tape stripping was performed on pig ears to establish the 
penetration depth of the model drug (aciclovir) from the formulations mentioned 
above (pure DPPC, CS coated liposomes and aqueous CS-solution). According 
to Herkenne et al. and Lindemann et al. data obtained in ex vivo on pig ear are 
comparable to those observed in vivo in humans [27, 28]. The most SC has 
been removed after approximately 40 strips confirmed by TEWL values of 80 
gm-2h-1 [29]. 
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Figure 2 Cryo-TEM micrographs of a) pure DPPC liposomes and b) CS coated DPPC 
liposomes 
 a)          b) 
   
 
The maximal penetration depth of aciclovir was detectable until the 10th strip 
from all three tested formulations (Fig. 3abc.). The TEWL values measured 
before and after the tape stripping were increased from about 14 to 30 gm-2h-1. 
This is in accordance with findings of electron microscopy studies on humans, 
where liposomes did not penetrate deeper than the horny layer [30]. The 
findings of presents work are also in agreement with other studies, where 
particles greater than 10 nm (we produced liposomes of ~90nm) did not 
penetrate the SC [31, 32]. The concentration of aciclovir in SC was related to 
the amount of corneocytes on each tape strip analysed by IR densitometer [20]. 
As seen in Table 3 the formulations applied did not significantly influence the 
amount of removed corneocytes in the first strip in comparison with untreated 
skin. Also the difference between the formulations considering the amount of 
removed corneocytes was not evident (Fig. 3abc.). Aciclovir from the aqueous 
CS-solution was detected in significantly higher amount on the skin surface, 
which was presented by the first tape strip, than from liposomal formulations 
(Table 3) indicating the better aciclovir penetration from liposomes. This was 
expected since liposomes have been claimed to improve drug deposition within 
the SC [33]. As seen also in Table 3, CS coated liposomes induced significantly 
improved aciclovir penetration into the SC compared to pure liposomes. This 
was in agreement with our previously published data: aciclovir penetrated 
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greater from CS coated liposomes than from CS free liposomes [10]. One of 
the reasons might be the positive charge of CS, leading to tight SC adhesion. 
 
a) 
 
 
b) 
 
 
 c) 
 
 
Figure 3 Penetration profile of the aciclovir containing formulations: a) aqueous CS- 
solution, b) DPPC liposomes and c) CS coated liposomes 
75 Specific topics 
 
Table 3 Aciclovir concentration in the first tape strip of the removed stratum corneum 
 
 
Untreated  
skin 
 Skin treated with 
CS-DPPC 
Skin treated with 
DPPC 
Skin treated with  
CS-solution 
 
      
Corneocytes 
(%) 
19.80 ± 4.66
a  
21.02 ± 0.96
a 
18.77 ± 1.45
a 
24.32 ± 1.55
a 
Aciclovir 
(µg/cm²) 
- 
 
13.89 ± 2.79
b 
18.99 ± 2.51
b 
25.26 ± 2.85
b 
Values are means ± SD of six experiments. 
 
a 
P > 0.05 (Tukey‘s test) 
 b 
P < 0.05 (Tukey‘s test) 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 Conclusion 
The FTIR results of this work appear to confirm the physiological similarities 
between pig skin and human skin: pig skin makes a good skin model for FTIR 
studies. Dermatomed abdominal porcine skin was especially suitable for this 
experiment due to its simple preparation. The skin treatments with liposomal 
formulations resulted in a partially decreased orthorhombic organisation or 
reduced barrier function. These data were confirmed by penetration studies. 
Using the tape stripping method the higher aciclovir penetration from CS 
coated liposomes versus polymer free liposomes was observed, verifying our 
previously published studies.   
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Abstract 
Phytosphingosine (PS) is a promising compound in skin formulations, 
considering its application in the treatment of acne and different inflammations 
as well as in the ‗anti age‘ cosmetics. PS, as an active substance was 
incorporated in DPPC liposomes intended to standard diffusion experiments, 
where dermatomed porcine skin was mounted in FRANZ-cells. The proved skin 
retention was about 5.5% (w/w) after 24 hours and about 6.8% (w/w) after 48 
hours of the applied PS amount, whereas only about 0.05% (w/w) and about 
0.07% (w/w) PS, respectively, could be observed in the acceptor medium. To 
increase analytical sensitivity PS was derivatised by o-phtalaldehyde (OPA) 
reagent and analysed by HPLC with fluorescence detection. The higher amount 
of PS within the skin symbolised an interaction with lipid structures in skin. 
Further evaluation of this interaction was accomplished by applying microDSC 
studies of PS with DPPC as a model membrane. For this purpose liposomes 
were prepared by increasing PS content. The characteristic endothermic peak 
observed for the single system was shifted to a slightly higher temperature and 
broadened as the mole fraction of PS increased. This might be the effect of 
mixing of PS with DPPC. An addition of 10 mol% PS resulted in more than 
double sized particles pointing to a possible change in the liposomal shape.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: DPPC-liposomes, phytosphingosine, DSC, OPA-reagent 
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1 Introduction 
The free sphingoid base phytosphingosine (PS) is naturally found in cell 
membranes of a human body and is present in small amounts in the epidermis 
[1]. PS is involved in keratinocytes differentiation and anti-inflammation [2]. In 
several studies PS showed anti-microbial properties against probionibacterium 
acnes and staphylococcus aureus and therefore effectively reduced signs of 
acne. Furthermore, there are investigations confirming that PS reduced 
redness of inflamed skin [3, 4]. Its positive influence on the skin permeation of 
fludrocortisone acetate and flumethasone pivalate in nanoemulsions 
formulations was documented by our group [5]. Recently an additionally 
preventive effect of PS on UV-induced decrease of pro-collagen was 
demonstrated in human dermal fibroblasts. Moreover, PS showed the inhibition 
of UV-induced IL-6 and COX2 gene expression. These results indicate that 
topically applied PS has anti-aging properties pointing to the potential use of 
PS as a therapeutic agent in the prevention and treatment of extrinsic aging [6] 
Due to all these studies, PS could be considered as an ideal active ingredient 
for different pharmaceutical and cosmetic applications whose biological activity 
can be enhanced by the use of an appropriate formulation. DPPC liposomes, 
spherical bilayer vehicles, have been chosen due to ability to encapsulate oil 
soluble components, increase their stability and maintain their activity in 
different environments [7]. Moreover, they are able to increase concentration of 
the compound in the epidermis and in the deeper layers of the skin probably 
through the similarity of their lipid bilayer to that in the skin [8]. 
In the first part the PS amount of skin penetration as well as skin retention from 
DPPC liposomes were investigated. For this purpose we performed diffusion 
studies on dermatomed porcine skin placed in FRANZ cells. The analytical 
method following derivatisation of PS involving HPLC was successful. It was 
simple, sensitive and exact, due to fluorescence detection. 
In the second part DPPC liposomes were used as model membranes to gain 
more information about their interaction with PS. MicroDSC studies 
investigating the influence of PS on DPPC thermotropic behaviour were 
selected.  
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2 Materials and Methods 
 
2.1 Materials 
1,2-Dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) was purchased from 
Lipoid (Switzerland). The product was Lipoid PC 16:0/16:0. According to its 
specification the content of phosphatidylcholine related to the dry weight was at 
least 99 %. Phytosphingosine was kindly provided by Degussa (Cosmoferm 
BV, NL). All other chemicals used in this study were of analytical reagent grade 
and were used as received without any further purification. 
The chemical structures of DPPC and PS are presented in Figure 1.  
 
a 
 
b  
 
 
Figure 1 (a) Chemical structure of DPPC and (b) chemical structure of PS  
 
2.2 Preparation of Liposomes 
DPPC liposomes were prepared according to a modified method of Thompson 
et al. [1]. Briefly, the phospholipid powder was dispersed in distilled water at 
60°C in an end concentration of 2.5% (w/w) and magnetically stirred until the 
powder was completely dissolved and thoroughly mixed using an ultra-Turrax 
(Omni 500). Afterwards the dispersion was homogenised with a high-pressure 
homogeniser (EmulsiFlex-C3, Avestin) for sixteen times at approximately 1100 
bar.  The liposomes were kept at 4 °C over night and characterised the day 
after in terms of mean particles size and PDI. Into these liposomes PS was 
incorporated directly in the following concentration: 2.5, 5 and 10 mol%, 
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respectively, and mechanically stirred for 24 hours at 60°C. The resulting 
liposomes were used for microDSC studies. For the diffusion experiments, 
liposomes loaded with 0.2% (w/w) PS were prepared in the same conditions. 
 
2.3 Diffusion studies  
In vitro permeation studies with porcine abdominal skin were performed as 
previously reported [9]. To obtain optimal sink conditions the receptor 
compartment was filled with 2 ml of 0.02 M phosphate buffer adjusted with 
lactic acid to pH 5. Since the concentration of PS actually used in cosmetics is 
0.05-0.2% (w/w), about 0.5-0.7 ml of 0.2% (w/w) PS-loaded liposomes were 
applied to the skin surface. Application of the liposomes was defined as the 
starting point of the procedure. Two independent sets of experiment were 
performed: one for 24 and one set for 48 hours. Samples were drawn, 
centrifuged at 17 586×g for 6 minutes. Subsequently the supernatants were 
discarded and frozen at -20 °C. They were then freeze-dried under the 
following conditions: at -30 °C for 3 hours and afterwards at -55 °C over night. 
The lyophilisates were resuspended in ethanol. Each batch was derivatized 
with OPA-reagent prior to quantification by HPLC.  
Additionally experiments were performed in order to analyse the content of the 
permeated PS in the skin 24 and 48 hours after application, respectively. At the 
end of each experiment sample-applied skin was wiped with paper than sliced 
and homogenised with a defined amount of ethanol, vortexed for 30 s and 
stirred over night. After centrifugation, supernatants were derivatized with OPA-
reagent and quantified by HPLC as described in 2.4.  Due to the naturally 
occurring PS in the epidermis we additionally carried out parallel experiments 
with PS-free liposomes. The measured PS concentration in the skin was about 
0.1 µg±0.03 per cm² and therefore negligible.  
 
2.4 OPA-reagent derivatization and HPLC analyses  
The OPA-reagent derivatization was accomplished as previously described by 
Min et al. [10]. Briefly, the sample solution was mixed with OPA reagent (5 mg 
o-phtalaldehyde, 25 µl 2-mercaptoethanol, 0.5 ml ethanol and 50 ml borate 
buffer pH 10.5) in 1:1 ratio for 2 min and incubated at room temperature for 30 
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min. The eppendorf tube was light protected to prevent degradation of OPA 
reagent [10].   
The HPLC analysis was performed using C-18 RP column (Nucleosil 100-5, 
250 mm x 4 mm, Macherey-Nagel, Germany) at 1 ml/min flow rate, with 
acetonitrile/water 90/10. The fluorescence intensity of the eluate was monitored 
at a wavelength of 370/460 nm excitation/emission by fluorescence detector 
(LS40, Perkin Elmer). Ethanol standard solutions of PS in the range from 0.3 to 
100 µg/ml (n=7) were derivatised with OPA-reagent and used to construct the 
calibration curve. Linearity was determined by the elaboration of three standard 
calibration curve (every fresh prepared). A very high correlation of 0.9998 ± 
0.0002 was obtained. The deviations of all points of calibration curve of PS 
were in the range of 1.1 to 2.5% of the slope of the corresponding regression 
equation. 
 
2.5 Particle size measurement of liposomes   
The mean particle size and size distribution were determined by photon 
correlation spectroscopy with a Zetasizer Nano ZS (Malvern, UK) at 25°C. The 
liposomes dispersion was diluted to the appropriate concentration with 
deionised water after 24 hours of preparation. The size distribution was 
represented by the polydispersity index (PDI) values. The measurements were 
performed using a He-Ne laser at 633nm.  
 
2.6 Micro-Differential scanning calorimetry (microDSC) studies 
Differential thermal analysis was performed using a Setaram III micro-
calorimeter. Samples of pure and PS loaded liposomes, prepared as described 
in 2.2 were scanned.  The measurements conditions were: 1°C/min for the 
scanning rate over the temperature range 15-65°C, using purified water as 
reference. Thermal transitions were calculated using Setsoft 2000 Setaram 
software. After baseline subtraction, raw power data were converted to molar 
heat capacity data. Baselines were fitted to the pre-transition and main 
transition regions using a linear baseline function so that transition 
temperatures and enthalpies of reaction could be calculated for each lipid 
concentration 
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2.7 Statistical data analyses 
Results of all studies are expressed as the means of at least three experiments 
± SD. Statistical data analysis was performed using t-test with P < 0.05 as 
minimal level of significance. 
 
3 Results and Discussion 
Due to increasing number of atopic eczema and pruritic diseases, new dermal 
preparations with the anti-inflammatory PS are of a great interest. Recently, 
additional penetration enhancing effect on the skin permeation of fludrocortison 
acetate and flumethasone pivalate was shown [5]. Therefore, PS could have 
the extra benefit of reducing topical corticosteroids acting as a multifunctional 
drug.  
In a first part of our research the amount of penetrated PS through porcine skin 
was measured. Due to the high lipophilicity of the PS (LogP 5.18), it could be 
expected that its main amount would be restored within the skin. In pre-liminary 
experiments it was seen that an HPLC analytic of PS with UV detection could 
not be used due to the very small PS amount remained under the detection 
limit. Therefore a more sensitive method using fluorescence detection was 
achieved. To gain a fluorescent detectability PS was labelled by                       
o-phthalaldehyde (OPA) reagent. Previously this method was useful for 
measurement of different sphingoid bases in biological samples [10]. The 
derivatisation relied on chemical reaction between o-phthalaldehyde and the 
primer amine group of PS in presence of reduced sulphur compound 
mercaptane. The obtained product, iso-indole, was analysed by HPLC using 
fluorescence detection. Diffusion experiments were run for 24 and 48 hours, 
respectively, after which the skin was shredded and analysed for PS. The 
applied amount of liposomes corresponded to an infinite dose.  As seen in 
Table 1 after 24 hours about 5.5% (w/w) and after 48 hours about 6.8% (w/w) 
of the applied PS amount was retained within the skin whereas only a small PS 
concentration of about 0.05 % (w/w) and about 0.07% (w/w) could be detected 
in the receiver compartment after 24 and 48 hours of diffusion, respectively. 
Interestingly no significant increase of PS in the acceptor medium can be 
achieved after 48 hours compared to 24 hours of diffusion. This result may 
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indicate an interaction of PS with structures within the skin. 
 
Table 1 Skin retention, cumulative permeated amount and amount in the donor 
compartment of PS in % of the applied amount after 24 hours (one set of experiments, 
and after 48 hours (one set of experiments) of diffusion  
 
Time (hours) PS (donor) 
(%) 
PS (retained) 
(%) 
PS permeated amount 
(%) 
24 94 ± 9 5.5 ± 2.4 0.05 ± 0.002 
 48 93 ± 16 6.8 ± 0.8 0.07 ± 0.002 
 Values are means ± SD n=3 
 
In order to obtain a better understanding of the mechanism of this interaction of 
PS, microDSC studies with DPPC as a model membrane were performed [11, 
12]. Although we are aware that the lipid composition of skin is completely 
different, DPPC liposomes, due to their, simplicity, were used as a model 
membrane for many other studies [13-15]. 
Since DPPC is a widely used model for lipid bilayers and its transition 
temperature Tmax can be easily measured as it has a narrow main endothermic 
peak at 41.4 °C (gel-to-liquid crystalline phase Pß´Lα), where the lipid acyl 
chains in an all-trans configuration undergoing a chain melting transition at a 
temperature, Tmax, to liquid crystalline phase with the chains having both trans 
as well as gauche configurations [11, 15, 16]. A smaller pre-transition, which 
appears near 34.4°C reflecting the lamellar gel to rippled gel (Lß´ Pß´) 
transition in the gel phase [11, 13, 15-17] The pre-transition has been generally 
attributed on the surface structure of the vehicle and is related to rotations of 
the phospholipid head groups or transformation in the lamellar structure and 
changes in the hydrocarbon chain packing [13]. Figure 2 gives the microDSC 
curves of the DPPC-PS loaded liposomes. As seen in Table 2, the 
characteristic endothermic peak observed for the single system is shifted to a 
slightly higher temperature and broadened as the mole fraction of PS 
increased. This effect on main transition endotherm may be explained as a 
result of mixing of PS with DPPC. This is in agreement with other studies 
investigating the similar structured stearylamine interacting with DPPC [18]. In 
other words, the higher transition temperature observed from the compositions 
of DPPC and PS may indicate closer packing of the DPPC and PS molecules 
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forming the lamellar bilayers. On the one hand the preferential partition of the 
lipophilic compound, PS, into the lipid domains of the bilayer structure by 
incorporation is expected. On the other hand the disappearance of the pre-
transition (Table 2) indicates an interaction with the polar region as well [13, 
15]. Moreover, an incorporation of 10 mol% PS was able to increase the 
liposome size more than twice (Table 3). This might be explained as a change 
of the shape of multilamellar vesicles (MLV) to large unilamellar vesicles (LUV) 
and due to the charge effect of PS [5, 19, 20]. However, TEM microscopy 
studies have to be performed to confirm this hypothesis. 
 
Table 2 Transition temperature and enthalpy values of DPPC liposomes with and 
without PS  
 
Mol % 
PS 
Tmax (°C) Linear Onset (°C) Enthalpy (J/M) 
      0 
     0 
 
 
 
 
34.4 ± 0.3 pre 
41.4 ± 0.1 main 
33.5 ± 0.6 pre 
40.1 ± 0.1 main 
gggggggggg.4 ± 0.1 
main transition 
40.1 ± 0.1 main 
transition 
30 ± 1 pre 
30600 ± 430 main 
 
  2,5 
 
41.7 ± 0.1 
 
39.8 ± 0.0 
 
44000 ± 2000 
 
     5 
 
41.8 ± 0.0 
 
40.3 ± 0.3 
 
40000 ± 15000 
 
10 
 
42.4 ± 0.1 
 
 
40.0 ± 0.2 
 
88000 ± 16000 
 Values are means ± SD n=3, pre=pre transi io  temp.; main=main transition temp. 
 
 
 
Table 3 The effect of incorporation of PS into 2.5% (w/w) DPPC liposomes on mean 
particle size, polydispersity index (PDI) and pH-values  
 
Mol% PS Particle size (d.nm) PDI pH 
0  81 ± 6 0.24-0.25 6.3 ± 0.2 
   2.5            152 ± 7 0.29-0.41 8.4 ± 0.0 
5 166 ±10 0.26-0.48 8.3 ± 0.1 
10            178 ± 7 0.34-0.50 8.6 ± 0.0 
Values are means ± SD n=5  
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Figure 2 Representative microDSC endotherms of DPPC liposomes containing 0-10 
mol% PS respectively. Tmax of DPPC is 41.4°C as indicated with an arrow 
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4 Conclusion 
In penetration studies with PS loaded DPPC liposomes it could be proven, that 
PS is retained in skin in relevant amounts. This seemed to be due to PS-lipid 
interactions seen in microDSC studies, indicating a closer packing of DPPC 
and PS in model membranes. 
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5 Conclusion 
The present thesis is concerned with skin application of nanoparticulated 
systems based on CS-TPP and DPPC, their manufacture and characterisation. 
In the first part, LC-MS data are used to show that CS-TPP nano-carriers had 
an improving effect on the chemical properties of aciclovir, slowing its photo-
oxidation into the degradation product 9-((2-hydroxyacetyl) methyl)-guanine 
under day-light exposure in comparison to its aqueous solution. Comparing 
aciclovir penetration studies in vitro from the CS-TPP nanoparticles 
demonstrated that nanoparticles with a larger size (~ 650 nm) showed greater 
aciclovir diffusion through porcine skin than nanoparticles with a smaller size (~ 
350 nm). In conclusion the higher CS content as well as a surface charge 
density of the larger nanoparticles might be the reason of this improved 
penetration. 
Coating of DPPC liposomes with CS and EU improved the liposomes‘ stability 
in terms of particle size and PDI. Coated DPPC liposomes with a size of ~ 90 
nm showed approximately the same order of aciclovir penetration as the 
smaller CS-TPP nanoparticles (comparing 10h with 8h studies). The 
permeation of aciclovir and minoxidil from uncoated DPPC liposomes was 
significantly lower in comparison with coated DPPC liposomes, what again is 
inducing on CS ability as the penetration enhancer. Tape-stripping studies on 
pig ears confirmed these results. Using different formulations the amount of 
aciclovir in the first layer of the stratum corneum, presented by the first strip, 
was compared. This demonstrated the following results: CS-DPPC liposomes > 
DPPC liposomes > aqueous CS-solution. Moreover, conformational changes of 
skin lipids measured by FTIR spectrophotometer correlated to the penetration 
depth of aciclovir from the liposomal formulations. 
Interaction of drugs as aciclovir, minoxidil and PS, having different logP, with 
DPPC bilayer was shown by microDSC thermograms. It was first thought that 
hydrophilic drugs connect with aqueous core whereas strong lipophiliyc drugs 
as PS integrate with lipidic domain. The microDSC results displayed either 
shifting or disappearance of the pre-transition peak as well as alteration of the 
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main transition peak by all three tested drugs, which could be interpreted as a 
drug interaction with both regions. If transferred on the skin bilayer we might 
say that drugs penetrate bonding across lipids, but also with hydrophilic region 
around corneocytes.  
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9 Abbrevations 
ATR 
CS 
CS-TPP 
DPPC 
DSC 
EE 
EU 
FTIR 
LC 
LC-MS 
MPS 
OPA 
PS 
PDI 
SC 
TPP 
ZP 
Attenuated total reflectance 
Chitosan 
Chitosan-Tripolyphosphate 
Dipalmitoylphosphatidylcholine 
Differential scanning calorimetry 
Encapsulation efficiency 
Eudragit EPO 
Fourier transform infrared spectrometry 
Loading capacity 
Liquid chromatography-mass spectrometry 
Mean particles size 
o-phthalaldehyde  
Phytosphingosine 
Polydispersity Index 
Stratum corneum 
Tripolyphosphate 
Zeta potential 
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